AUTHOR INDEX

Abdel-Monem, M. M. 94, 102
Abe, O. 356, 379
Abeloff, M. D. 98, 99, 104, 105
Abou-Gharbia, M. 357, 358, 362, 363, 365, 379
Abou-Samra, A. B. 203, 207
Abrams, R. 287, 297
Acton, J. M. 357, 364, 365, 380
Adams, J. D., Jr. 185, 189
Adelstein, R. S. 250, 268
Agostinis, P. 241–270
Agranoff, B. W. 119, 131
Aguilera, G. 203, 207
Ahmed, K. 241, 263, 266
Ahmed, S. A. 365, 369, 381
Aiello, P. D. 159, 161, 162, 170
Ailhaud, G. 370, 382
Aitken, A. 262, 269
Akerboom, T. P. M. 176, 177, 179, 181, 182, 187, 188
Akerman, M. 288, 290, 291, 293, 297, 298
Albert, D. A. 292, 298
Alemany, S. 242, 243, 247, 248, 250, 253, 267
Alexandrova, M. 37, 60
Alison, R. D. 216, 224
Allan, J. A. 357, 364, 365, 380
Allegra, C. J. 157, 158, 163, 169, 170
Allegri, G. 273, 282
Allen, J. R. 294, 299
Allfrey, V. G. 278–280, 282
Altin, J. G. 82, 88
Amakawa, A. 63, 86
Anderson, D. E. 357, 379
Anderson, G. 96, 103
Anderson, M. E. 179, 181, 187, 216, 224
Anderson, W. B. 137, 143
Andersson, P. O. 63, 66, 74, 86
Angus, C. W. 370, 382
Antoniades, H. N. 230, 237
Antonucci, A. 276, 282
Anzano, M. A. 227, 230, 237
Aoki, T. 336, 344, 351
Appelgren, L. E. 211, 223
Applezweig, N. 364, 365, 367, 381
Arias, I. M. 181, 188
Armour, R. 225, 234, 236
Asaoka, K. 176, 187
Ashida, Y. 225–237
Assoian, R. K. 227, 230, 232, 237
Auberger, P. 241, 266
Austen, K. F. 136, 143, 211, 220, 222, 223
Aw, T. Y. 185, 189
Axelsson, K. 178, 179, 187
Aylward, J. H. 242, 246, 249, 266, 268

Babson, J. R. 176, 187
Baccanari, D. P. 3–15
Bachrach, U. 97, 103
Bacon, P. E. 293, 295, 298, 299
Bailey, B. D. 157, 169
Bailey, K. R. 185, 188
Baldwin, J. H. 225, 234, 236
Balinska, M. 147, 149, 150, 154
Balinsky, J. B. 45, 60
Balks, H. J. 65, 66, 67, 68, 74, 81, 87
Ballé, C. 63–88
Ballou, D. P. 165, 170
Banks, P. A. 356, 378
Baril, B. 295, 299
Baril, E. 295, 299
Barnabei, O. 271–283
Barnes, D. 228, 237
Barrack, E. R. 275, 276, 282
Bartlett, P. A. 108, 113
Bartoli, G. M. 181, 188
Bartolomé, J. 96, 103
Bartrons, R. 33, 60
Baugh, C. M. 157–162, 165, 169, 170
Baulieu, E. E. 355, 378
Baumgartner, W. 184, 188
Baylin, S. B. 94, 96, 98, 99, 101, 103–105
Beaconfield, P. 357, 379
Beato, M. 54, 61
Beatty, P. W. 176, 187
Beckh, K. 63–88
Beckmann, R. 184, 188
Beddell, C. R. 12, 14
Bednarek, J. M. 157, 169
Beidler, D. 177, 178, 187
Belay, D. 31–61
Bell, J. R. 232, 237
Bell, R. M. 370, 382
Belle, M. V. 127, 131
Belunis, C. J. 4, 14
Ben, T. 97, 103
Bend, J. R. 176, 187
Benes, P. 356, 375, 378

Benhamou, J. P. 64, 87
Ben-Jonathon, N. 42, 60
Benkovik, P. A. 324, 329, 333
Benkovik, S. J. 320, 324, 327, 329, 330, 332, 333
Berger, R. A. 118, 129, 132
Bergeron, R. J. 94, 95, 102
Bergmeyer, H. U. 65, 87
Bernard, C. 63, 86
Bernhohr, D. A. 370, 371, 382
Bernström, K. 211, 212, 215, 217, 220, 223
Berridge, M. J. 45, 47, 60, 117, 118, 126, 129, 131
Berthelot, P. 64, 87
Bertino, J. R. 3, 8, 14, 15, 24, 27, 148, 151, 152, 154, 155, 158, 161, 164–166, 170
Besserer, J. A. 301–316
Bethell, D. R. 93, 101
Betteridge, D. 136, 143
Bey, P. 93, 94, 99, 101, 109, 113
Bierring, F. 63, 66, 79, 86
Bilham, T. 262, 269
Billheimer, J. 366–368, 381
Billi, A. M. 273, 278, 279, 282, 283
Bilzer, M. 176, 181, 182, 187, 188
Birdsall, B. 8, 14
Bittner, G. 345, 352
Blacher, R. 227, 230, 237
Black, D., Jr. 99, 105
Blackmore, P. F. 48, 60, 61
Blakley, R. L. 8, 11, 12, 14
Blanc, O. 99, 105
Bleskan, J. 327, 330, 331, 333
Bloomfield, V. A. 107, 112
Boccuzzi, G. 357, 379
Bohlen, P. 93, 101
Böhme, H.-J. 31–61
Bolanowski, M. A. 370, 371, 382
Boldizsar, M. 350, 352
Bolin, J. T. 12, 14
Bolkenius, F. N. 93, 101
Bonino, L. 357, 379
Bonta, I. L. 184, 188
Booth, J. W. 294, 299
Borchardt, R. T. 107, 108, 112
Borin, G. 260, 269
Boritzki, T. J. 301–316, 338, 339, 342, 351
Bosia, A. 357, 379
Bot, G. 255, 256, 269
Boutwell, R. K. 97, 98, 103, 104
Bowers, S. W. 20, 27
Bragt, P. C. 184, 188
Brandt, H. 255, 269
Branum, E. L. 230, 237
Brigelius, R. 175–189
Brignardello, E. 357, 379
Brind, J. L. 355, 378
Brion, F. 211, 223
Brodie, A. E. 176, 187
Brom, J. 216, 224
Bross, T. E. 117–119, 129, 131, 132
Brown, G. B. 301, 315, 316
Brownsey, B. 356, 379
Brunati, A. M. 260, 269
Brunsmann, M. 66, 74, 87
Bueurs, U. 63–88
Bulbrook, R. D. 356, 379
Bullough, W. S. 234, 237
Burchall, J. J. 3, 6, 14, 15
Burgen, A. S. V. 8, 14
Burridge, J. M. 12, 14
Bush, I. E. 201, 207
Buss, J. 275, 282
Bussolotti, D. L. 108, 109, 112
Butenandt, A. 355, 378
Butler, M. 184, 188
Bygrave, F. L. 82, 88

Cadenas, E. 183, 185, 188, 189
Cake, M. H. 47, 60
Callahan, M. 96, 103
Cameron, E. H. D. 356, 379
Campbell, H. 356, 379
Camps, T. 260, 262, 263, 269, 270
Canellakis, Z. N. 91, 92, 100, 108, 109, 112, 241, 264, 266, 270
Cantor, C. R. 278–280, 282
Caperelli, C. A. 324, 329, 333
Capitani, S. 271–283
Capito, K. 241, 266
Capraro, M. A. 215, 224
Caramelli, E. 273, 274, 276, 278, 282, 283
Carmen, G. M. 4, 14
Carpenter, G. 195, 207
Carr, F. P. 212, 223
Carroll, P., Jr. 184, 188
Carter, G. L. 293, 298
Carter, S. K. 17, 27
Carton, H. 63, 86
Casara, P. 94, 101, 109, 113
Casazza, J. P. 366, 367, 381
Casero, R. A. 91–105
Casey, L. M. 365, 369, 381
Cashmore, A. R. 165, 166, 170
Caston, J. D. 148, 154
Catt, K. J. 203, 207
Cavanaugh, P. F. 95, 102
Chabner, B. A. 157, 158, 163, 169, 170
Champness, J. N. 12, 14

Chan, K. K. 151, 152, 154
Chanarin, I. 165, 170
Chando, C. 366, 367, 381
Chang, B. K. 99, 105
Chang, C. C. 98, 99, 104
Chang, C.-H. 288, 290, 291, 293, 297, 298
Charest, R. 48, 61
Chaudhari, P. R. 107, 112
Chello, P. L. 165, 166, 170
Chen, E. Y. 232, 237
Chen, S. Y. 107, 108, 112
Cheng, Y.-C. 287, 288, 290, 291, 293, 296–298
Cheng, Y.-S. 319–333
Chessa, G. 260, 269
Chesterton, C. J. 275, 282
Chettur, G. 320, 324, 329, 333
Cheung, W. Y. 254, 262, 268
Chiba, P. 295, 299
Childs, C. B. 232, 237
Christoff, M. 180, 188
Cichowicz, D. 151, 152, 155, 161, 164, 170
Cilento, E. V. 72, 87
Civin, C. I. 96, 103
Clarke, N. 118, 131
Claverie, N. 99, 105
Cleary, M. P. 365–368, 381
Cleland, W. W. 8, 15
Cocco, L. 11, 12, 14, 271–283
Cockcroft, S. 45, 47, 60
Coddington, A. 320, 330, 332
Coffey, D. S. 275, 276, 282
Cohen, P. 242, 243, 247, 248, 250, 253, 254, 256–259, 262, 267–270
Cohen, S. 195, 207
Colburn, N. 97, 103
Coleman, D. L. 364, 365, 381
Coleman, R. A. 370, 382
Collins, T. 288, 297
Collison, M. W. 177, 178, 187
Colman, P. D. 151, 152, 154, 161, 164, 170
Connolly, T. M. 117–119, 131
Cook, J. 151, 152, 155, 158, 159, 161, 164, 169, 170
Coon, H. G. 225, 236
Cooper, R. H. 117, 132
Coppoc, L. 98, 104
Corey, E. J. 211, 223
Cornell, R. 272, 281
Corpéchot, C. 355, 378
Cory, J. G. 287–299
Coupar, B. H. 275, 282
Courcelles, D. C. 127, 131
Courtney, L. F. 327, 333
Coward, J. K. 95, 102, 107–113, 147, 151, 152, 154, 155, 161, 164–166, 170
Criss, W. E. 241, 266
Cristofalo, V. J. 360, 361, 380
Crouch, D. 249, 268
Crowley, J. J. 356, 379
Cruetz, C. E. 137, 143, 144
Csortos, C. 255, 256, 269
Curthoys, N. P. 216, 224

Dahlén, S. E. 220, 224
Dahmer, M. K. 204, 207
Dalley, N. K. 301, 316
Daluge, S. 8, 10–12, 14
Daniel, P. M. 71, 87
Dannenbaum, H. 356, 378
Danzin, C. 94, 99, 101, 105, 109, 113
Dart, L. L. 227, 230, 237
Daubner, C. 320, 327, 329, 330, 332, 333
David, F. 288, 297
Davis, J. R. 366, 381
Davis, L. 158, 159, 161, 170
Dawson, R. M. C. 118, 131
Deacon, R. 165, 170
Deangelis, L. M. 165, 166, 170
Defreyn, G. 260, 262, 269, 270
Delia, T. J. 301, 316
DeMonti, M. 232, 237
Denis, P. 64, 87
Denton, J. E. 336, 344, 351
Denzlinger, C. 221–224
Depaoli-Roach, A. A. 252, 256, 268
Derynck, R. 232, 237
Dettmer, D. 31–61
DeVita, V. T. 309, 316
Dewey, H. K. 31, 34, 40, 59
Dewulf, H. 63, 86
Dhumeaux, D. 64, 87
Diamond, L. 195, 207
Dickson, A. J. 241, 266
Diekema, K. A. 98, 104
Dillard, R. D. 212, 223
DiSalvo, J. 242, 248–251, 257, 267, 268
Dixon, J. F. 117–132
Dixon, M. 342, 352
Doig, M. T. 21, 27, 151–153, 155, 157, 169
Don, S. 97, 103
Donath, T. 63, 66, 79, 86
Donato, H. 19, 27
Donohue, J. P. 296, 299, 336, 341, 351
Dougherty, T. F. 202, 207
Dowling, L. G. 137, 143, 144
Downes, C. P. 117, 131
Drake, J. C. 157, 158, 163, 169, 170

Dray, F. 355, 378
Drazen, J. M. 211, 223
Drobnik, J. 17, 27
Duch, D. S. 20, 27
Duchesne, M. C. 94, 99, 101, 104
Duffy, T. 17–27
Dunlap, R. B. 19, 27, 157–171
Dworkin, C. R. 360, 361, 380

Eaton, D. H. 232, 237
Eble, J. N. 336, 344, 351
Edwards, A. V. 63, 66, 74, 86
Eggleston, L. V. 180, 188
Elford, H. L. 287, 295, 297, 299
Elliott, H. 326, 333
Elliott, W. L. 215, 224
Ellis, W. W. 176, 187
Emanuelsson, H. 263, 270
Emiliozzi, R. 355, 378
Emrani, J. 336, 344, 351
Engstrom, Y. 291, 292, 298
Enno, T. L. 250, 251, 253, 268
Erdödi, F. 255, 256, 269
Eriksson, S. 288, 290–293, 297, 298
Ernest, M. J. 34, 60
Evans, C. A. 42, 60
Everson, W. V. 262, 269
Exton, J. H. 48, 60, 61

Facchini, A. 272, 281
Faderan, M. A. 215, 224, 336, 341, 344, 348, 351, 352
Fairman, D. K. 365, 366, 369, 381
Falck, B. 63, 66, 74, 86
Farewell, V. T. 356, 379
Farmer, S. R. 370, 382
Farr, A. L. 33, 60, 195, 207
Farrar, W. L. 137, 143
Farrelly, J. G. 225, 236
Feeney, J. 8, 14
Feigelson, P. 31, 59
Felaco, M. 278, 283
Feniuk, L. 211, 223
Fernandes, D. J. 158, 169
Ferry, N. 34, 48, 60
Feuerstein, G. 211, 220, 223
Fillingame, R. H. 96, 103
Filman, D. J. 12, 14
Fine, R. L. 157, 158, 169
Fischer, P. H. 345, 352
Fisher, E. A. 31, 46, 59, 60
Fisher, M. J. 241, 243, 257, 266, 267
Fisher, R. A. 177, 187
Fitzsimmons, B. 211, 223
Fleisch, J. H. 212, 223
Fleischer, A. E. 288, 291, 292, 297, 298
Flohe, L. 179, 184, 187, 188
Fluri, R. 320, 330, 332
Flury, Y. 320, 330, 332
Folker, J. E. 94, 102
Foo, S. K. 151, 154, 157, 169
Forrest, A. P. M. 356, 379
Forsch, R. A. 151, 152, 154
Forssmann, W. G. 63, 66, 79, 85
Forstad, C. M. 96, 103
Fossa, T. 263, 270
Foster, A. 211, 223
Foulkes, J. G. 248, 262, 268, 269
Fowler, S. K. 96, 97, 103
Fox, N. 366–368, 381
Fox, R. M. 294, 298
Fozard, J. R. 96–98, 102, 104
Franchi, M. 273, 282
Frank, M. 370, 382
Franson, R. C. 137, 144
Frappier, L. 291, 292, 295, 298
Freese, M. 287, 297
Freire, M. 180, 188
French, J. C. 301, 316
Frenster, J. H, 272, 274, 281, 282
Friedman, R. B. 178, 187
Friend, C. 96, 103
Frienkel, N. 118, 131
Frolik, C. K. 227, 230, 237
Fry, D. W. 157, 169, 301–316
Fujihira, E. 185, 188
Fujii, K. 23, 27, 168, 170
Fujimoto, T. 63, 70, 86
Fujimura, S. 288, 290, 297
Fukuda, A. 63, 86
Fukui, N. 288, 290, 297
Fukusen, N. 191, 192, 197, 198, 200, 206
Fukushima, D. K. 356, 379
Fung, C. 370, 382
Furukawa, M. 176, 187

Gain, K. R. 46, 60
Galanzi, A 273, 282
Galaway, R. A. 135, 143
Galivan, J. 147–155
Galletti, P. 93, 101
Ganapathi, M. K. 249, 268
Ganis, B. 95, 102
Garceau, D. 66, 75, 87
Gardemann, A. 63–88
Gardner, J. D. 127, 131
Gariglio, P. 275, 282
Garlich, J. R. 95, 102
Gasior, E. 4, 15
Gaumont, Y. 158, 169

Gawthorne, J. M. 168, 171
Gazdar, A. F. 99, 104
Gazitt, Y. 96, 103
George, S. 151, 152, 155, 161, 164, 170
Gergely, P. 255, 256, 269
Gerok, W. 182, 188
Gerstenecker, C. 179, 187
Geynet, P. 34, 48, 60
Ghose, C. 157–171
Giannina, T. 184, 188
Gibian, M. J. 135, 143
Gierson, H. 356, 379
Giertz, H. 184, 188
Gifford, D. 242, 248–251, 257, 267, 268
Gilbert, H. F. 176, 187
Gilmour, R. S. 272, 275, 281, 282
Girard, P. 280, 283
Girardier, L. 66, 74, 87
Gladstone, N. 341, 352
Gleave, E. N. 356, 379
Glover, J. L. 296, 299, 336, 341, 344, 351
Godman, G. C. 228, 237
Goeddel, D. V. 232, 237
Goldberg, N. D. 126, 131
Goldin, A. 309, 316
Goldman, D. A. 294, 299
Goldman, I. D. 157, 169
Goldthwait, D. A. 319, 326, 332
Goltzsch, W. 31–61
Gomperts, B. D. 45, 47, 60
Goodhardt, M. 34, 48, 60
Goodwin, G. 94, 99, 101, 104
Gordon, G. B. 355–382
Goris, J. 241–270
Gorman, S. D. 360, 361, 380
Goueli, S. A. 241, 263, 266
Goutas, L. J. 148, 149, 154
Graetz, H. 291, 292, 298
Graf, P. 175–189
Granner, D. K. 195, 207
Graslund, A. 291, 292, 298
Graw, S. 320, 332
Gray, J. W. 96, 103
Green, H. 370, 381, 382
Green J. M. 157–171
Green, K. C. 48, 60
Green, M. H. 275, 282
Greenfield, S. 225, 234, 236
Greengard, O. 31, 34, 40, 59
Greenway, C. V. 71, 75, 87
Gregorová, I. 356, 379
Griffin, C. A. 98, 99, 104, 105
Griffin, J. 96, 103
Griffiths, K. 356, 379
Grillo, M. A. 263, 270
Grimaldi, R. 370, 382
Grimm, L. M. 177, 178, 187
Grodin, J. M. 355, 378
Gross, T. S. 320, 332
Grove, J. 94, 96, 98, 99, 101, 102, 104, 105
Grove, J. L. 272, 281
Grundler, G. 17–27
Gudas, L. J. 289, 292, 297, 298
Guhlmann, A. 211–224
Gullick, W. J. 225, 236
Gurpide, E. 355, 378
Gustafsson, B. 211, 212, 223
Gutman, R. 99, 105

Häberle, D. 175, 176, 186
Haddox, M. K. 126, 131
Haeberle, J. R. 249, 268
Hagmann, W. 211–224
Haisch, K. D. 212, 223
Halsey, M. J. 165, 170
Hamberg, M. 144
Hamelehle, K. L. 301–316
Hamilton, S. R. 98, 104
Hammarström, S. 133, 143, 211, 212, 214, 215, 217, 219, 220, 222–224
Hammer, D. K. 211–213, 217–221, 223
Hammond, N. D. 204, 207
Handwerger, S. 129, 132
Hannonen, P. 97, 104
Hanoune, J. 34, 48, 60
Hansen, C. T. 366, 367, 381
Hanson, R. W. 31, 59
Happel, K. K. 157, 169
Harada, J. J. 96, 103
Hard, G. C. 357–359, 362, 365, 379, 380
Harding, H. R. 195, 207
Hards, R. 327, 330, 331, 333
Hare, J. R. 42, 60
Harel, L. 232, 237
Harper, T. W. 136, 143
Harrington, W. N. 228, 237
Hart, A. 45, 60
Hartmann, H. 63–88
Hathaway, D. R. 249, 268
Häussinger, D. 182, 188
Hayward, J. L. 356, 379
Heby, O. 95, 96, 103, 263, 270
Hecker, E. 195, 207
Hedeskov, C. J. 241, 266
Hedqvist, P. 220, 224
Hein, D. W. 220, 224
Heldin, C.-H. 225, 234, 236
Heller, J. S. 108, 109, 112
Hemmings, B. A. 258, 269
Henderson, E. 363, 380

Henderson, G. B. 23, 27
Henderson, J. F. 293, 294, 298
Henikoff, S. 320, 327, 329–333
Henney, J. E. 309, 316
Hennings, H. 97, 103
Herian, M. 356, 379
Hermann, J. 99, 105
Hermodson, M. A. 320, 333
Herrmann, A. 96, 103
Hers, H.-G. 33, 60
Hervatin, S. J. 94, 98, 101
Heston, W. D. W. 275, 276, 282
Hibasami, H. 92, 93, 101, 107–109, 112, 113
Hidaka, H. 203, 207
Higashi, T. 176, 187, 191, 206
Hikiti, K. 176, 187
Hilgertová, J. 356, 379
Hill, V. 184, 188
Hiraga, A. 242, 249, 266
Hirasawa, K. 117, 131
Hirota, K. 54, 61
Hirota, T. 54, 61
Hirsch, A. 370, 382
Hitchings, G. H. 3–15
Hluboky, M. 107, 112
Ho, K. W. 47, 60
Ho, P. P. K. 20, 27
Ho, R. 370, 382
Hoffman, B. B. 42, 60
Hoffman, J. L. 93, 101
Hofmann, E. 31–61
Hokanson, G. C. 301, 316
Hokin, L. E. 117–132
Holley, R. W. 225, 230, 234, 236
Holst, J. 63, 66, 74, 86
Holten, J. F. 47, 60, 201, 207
Höltta, E. 97, 104
Hood, S. S. 366, 367, 381
Hopkins, C. E. 356, 379
Hopper, S. 290, 298
Horecker, B. L. 137, 144, 195, 207
Horio, T. 225–237
Horwitz, A. F. 272, 281
Hosowaka, M. 242, 266
Hradec, J. 274, 282
Hsieh, P. 147, 151, 152, 154, 155, 161, 164, 170
Hsu, R. Y. 370, 382
Hsu, Y. M. 225, 232, 234, 236
Hua, X. Y. 220, 224
Huang, C. Y. 253, 268
Huang, W. 225–237
Huber, H. 211–224
Huberman, E. 96, 103
Huennekens, F. M. 17–27, 186, 170
Hughey, R. P. 215, 224
Huguenard, J. 96, 103
Hunting, D. 293, 294, 298
Hurlbert, R. B. 288, 293, 297
Hyde, E. I. 8, 14
Hyland, J. 98, 104

Ichihara, A. 48, 52, 61, 194, 206, 357, 359, 370
Ikegami, T. 340, 352
Imaoka, T. 249, 268
Imazu, M. 249, 268
Inagaki, M. 203, 207
Ingebritsen, T. S. 243, 248, 254, 257–259, 262, 267–270
Ingemansson, S. 63, 66, 74, 86
Inglese, J. 147, 154
Inoue, M. 181, 188
Irvine, R. F. 45, 47, 60, 117, 118, 131
Isham, K. R. 56, 61
Ishidoh, K. 191, 192, 197, 198, 200, 206
Ishizuki, S. 185, 188
Ito, I. 157, 169
Ito, N. 357, 359, 380
Ito, S. 63, 66, 79, 85
Iynedjian, P. B. 31, 59
Iype, P. T. 225, 236

Jackson, R. C. 294, 299, 301–316, 338, 339, 342, 351
Jacob, H. S. 179, 187
Jaenicke, L. 5, 14
Jaerhult, J. 63, 66, 74, 86
Jakschik, B. A. 117, 129, 131, 134, 143
Jakubowicz, T. 4, 15
Jandl, J. H. 179, 187
Janisch, S. 54, 61
Jänne, J. 92, 96–98, 101–104, 107, 112
Jansen, P. L. M. 212, 213, 217, 223
Jarrett, J. A. 232, 237
Jayaram, H. N. 335–352
Jeanrenaud, B. 66, 74, 87
Jefferson, L. S. 262, 269
Jenks, B. 366, 367, 381
Jenks, W. P. 19, 27, 162, 170
Ji, S. 71, 72, 74, 87
Jildevik, I. 291, 292, 298
Johnson, E. M. 278–280, 282
Johnson, T. 147–155
Jolivet, J. 158, 163, 169, 170
Jones, C. 320, 332
Jones, D. P. 185, 187
Joseph, S. K. 45, 47, 60, 117, 132
Jullien, M. 232, 237
Jung, M. J. 94, 101, 109, 113

Jungalwala, F. B. 118, 131
Jungermann, K. 63–88

Kaijser, L. 219, 220, 224
Kaleita, E. 356, 378
Kallen, R. J. 19, 27
Kallio, A. 97, 105
Kalton, G. 357, 379
Kamen, B. A. 148, 152, 154
Kaplowitz, N. 185, 189
Kapoor, C. L. 127, 131
Kato, K. 255, 268, 269
Kato, S. 48, 61
Katunuma, N. 191–207
Kaufman, B. T. 12, 14
Kawamoto, S. 203, 207
Keene, M. A. 327, 330, 331, 333
Kehinde, O. 370, 381
Keller, A. R. 355, 378
Kelly, E. 94, 95, 102
Kelly, T. J., Jr. 370, 371, 382
Kelsey, W. 97, 103
Kennedy, I. 211, 223
Kenney, F. T. 47, 56, 60, 61, 201, 207
Kensler, T. W. 360, 380
Keppler, D. 211–224
Kerc, E. 257, 269
Kern, D. L. 301, 316
Kesevan, V. 21, 27, 147–155
Khandelwal, R. L. 250, 251, 253, 268
Khorana, H. G. 128, 131
Kido, H. 191–207
Kiernan, J. W. 225, 236
Kihira, Y. 225–237
Kikkawa, U. 195, 207
Kikuchi, H. 242, 249, 266
Kikuchi, K. 242, 249, 266
Killewich, A. 31, 59
Killilea, S. D. 242, 246, 249, 255, 266, 269
Kimura, T. 225–237
King, L. E., Jr. 195, 207
King, M. M. 253, 268
King, R. W. 8, 10–12, 14
King, W. W. K. 98, 104
Kingsnorth, A. N. 98, 104
Kinne, R. 181, 188
Kinohara, N. 249, 268
Kisliuk, R. L. 158, 169
Kitajima, S. 33, 39, 60
Kizaki, H. 340, 341, 344, 352
Klee, C. B. 254, 262, 268
Klingberg, D. 252, 256, 268
Klinge, E. M. 295, 299
Klippenstein, G. L. 292, 298
Knox, W. E. 31, 59
Kobayashi, M. 255, 268, 269
Koberling, A. 291, 292, 298
Koch, H. K. 211, 223
Koch-Weser, J. 94, 96, 98, 99, 101, 102, 105
Kokkinakas, A. 242, 248–251, 257, 267, 268
Köller, M. 216, 224
Komarkova, E. 274, 282
Kominami, E. 191, 206
Komoriya, A. 227, 230, 237
König, W. 216, 224
Koo, A. 72, 88
Kornberg, A. 195, 207
Koropatnick, S. E. 289, 297
Kosower, E. M. 179, 187
Kosower, N. S. 179, 187
Kozak, E. M. 216, 224
Kramer, D. L. 94, 102
Kraut, J. 12, 14
Krebs, H. A. 180, 188
Kreft, A. F. 212, 223
Krehl, W. A. 357, 379
Kremer, J. 152, 154
Kremmer, T. 350, 352
Krishna, G. 127, 131
Krumdeick, C. L. 157, 169
Kucera, R. 292, 298
Kucharzewska, T. 4, 15
Kufe, D. 96, 103
Kumaoka, S. 356, 379
Kuo, J. F. 241, 266, 271, 272, 280, 281, 283
Kuri-Harcuch, W. 370, 382
Kusama, M. 356, 379
Kutzbach, C. 165, 170
Kwiat, M. A. 107, 112
Kyger, E. M. 137, 144

Lachmann, P. J. 98, 99, 104
Laemmli, U. K. 228, 237, 323, 333
Lai, M. H.-T. 341, 352
Lamb, L. C. 227, 230, 237
Lamers, W. H. 31, 34, 36, 59
Lands, W. E. M. 143
Lane, M. D. 370, 371, 382
Lang, A. 272, 281
Lange, R. 31–61
Langen, P. 291, 292, 298
Lapetina, E. G. 119, 131
Larsson, A. 293, 298
Lash, L. H. 185, 189
Lasser, G. W. 294, 299
Lassmann, G. 291, 292, 298
Laurence, E. B. 234, 237
Lauterberg, B. H. 185, 188, 189

Lautt, W. W. 63, 64, 66, 70, 71, 74, 75, 84, 86
Lawrence, B. 355, 378
Lazin, B. 366–368, 381
Leach, K. L. 204, 207
Lebeau, M.-C. 355, 378
LeCam, A. 241, 266
LeCam, G. 241, 266
Lederer, B. 33, 60
Lee, E. Y. C. 242, 246, 249, 255, 266, 268, 269
Lee, K.-L. 56, 61
Lee, L. 134, 143
Leeb, J. 184, 188
Lefer, A. M. 211, 220, 223
Lefkowith, J. B. 117, 129, 131
Lefkowitz, R. J. 42, 60
Lehmann, W. 291, 292, 298
Lehrman, S. R. 227, 230, 237
Leiter, E. H. 364, 365, 367, 381
Lenzen, R. 176, 187
Leopold, W. R. 301–316
Letts, L. G. 211, 223
Levin, J. 356, 379
Levin, R. M. 254, 268
Levin, V. A. 94, 98, 101
Levy, C. C. 98, 104, 180, 188
Levy, H. R. 356, 371, 375, 379
Lew, H. 185, 188
Lewis, A. J. 212, 223
Lewis, M. A. 195, 207
Lewis, R. A. 136, 143, 211, 220, 222, 223
Lewis, W. H. 289, 290, 297
Li, H.-C. 242, 249, 266, 268
Liang, I. Y. S. 72, 88
Liao, S. 241, 266
Lichti, U. 97, 103
Lieberman, S. 355, 378
Lieberman, I. 287, 297
Liepnieks, J. J. 215, 224, 341, 352
Liermann, B. 291, 292, 298
Littau, V. C. 278–280, 282
Loeble, R. B. 158, 170
Lomax, N. R. 309, 316
Lombardo, L. J., Jr. 356, 379
London, R. E. 11, 12, 14
Long, C. W. 191, 206
Look, A. T. 225, 236
Lopezs, A. 357, 379
Lorber, A. 184, 188
Loschen, G. 184, 188
Lowry, O. H. 33, 60, 195, 207
Lu, Y.-Z. 159, 161, 162, 170
Lucas, J. A. 365, 369, 381
Luftig, R. B. 295, 299
Lui, M. S. 215, 224, 302, 316, 335, 336, 338–342, 344, 348, 351, 352
Luk, G. D. 91–105
Lumb, M. 165, 170
Lundberg, J. M. 220, 224
Lutz, R. 158, 169
Lynch, C. J. 48, 61
Lyon, J. A. 158, 170

MacDonald, J. S. 309, 316
MacDonald, P. C. 355, 365, 369, 378, 381
Macho, L. 37, 60
Mackall, J. C. 370, 382
MacKenzie, R. E. 158, 160–162, 170
MacManus, J. P. 288, 290, 291, 297
Madsen, G. 326, 333
Mäenpää, P. H. 241, 266
Magasanik, B. 319, 320, 325, 326, 330, 332
Magee, P. N. 357, 358, 362, 365, 380
Magnum, M. 157, 169
Majerus, P. W. 117–119, 129, 131, 132
Makman, M. H. 202, 207
Malt, R. A. 98, 104
Mamont, P. S. 93, 94, 99, 101, 102, 104
Manalan, A. 254, 262, 268
Mannervik, B. 178, 179, 187
Mansell, M. M. 288, 289, 293, 297, 298
Manzoli, F. A. 271–283
Maraldi, N. M. 271–283
Marchiori, F. 243, 257, 258, 260, 267, 269
Marfat, A. 211, 223
Marinelli, F. 276, 282
Mariuzza, R. 108, 112
Markham, M. 356, 379
Marks, P. A. 356, 378
Marlowe, C. K. 108, 113
Marmorston, J. L. 356, 379
Martelli, A. M. 274–276, 278, 279, 282, 283
Martin, D. W. 291, 292, 298
Martin, R. L. 46, 60
Marton, L. J. 94, 96, 98, 99, 101, 103, 241, 266
Masaki, H. 226–229, 236, 237
Mashima, K. 225–237
Mathews, C. K. 294, 299
Matsui, I. 93, 101
Matsumoto, T. 133, 134, 136, 137, 143
Matteucci, A. 274, 276, 278, 279, 282, 283
Matthews, D. A. 12, 14
Matthews, K. D. 157–171
Matthews, R. G. 157–171

Mattheyse, F. J. 45, 60
Mauvais-Jarvis, P. 355, 378
Mayer, G. D. 94, 102
Mazzei, G. J. 241, 266, 280, 283
Mazzotti, G. 273–276, 278, 282
Mbensa, M. 357, 379
McAvinchey, D. 98, 104
McCairns, E. 326, 333
McCann, P. P. 91–95, 98–101, 104, 107, 112, 241, 266
McCullough, D. 212, 223
McCullough, J. L. 3, 8, 14
McCuskey, A. P. 63, 66, 79, 86
McCuskey, R. S. 63, 66, 72, 79, 86, 87
McDaniel, M. L. 129, 132
McFeeters, G. 365, 369, 381
McGuire, J. J. 147–155, 161, 164, 170
McIntyre, T. 216, 224
McMahon, J. B. 225, 236
Meggio, F. 241, 260, 266, 269
Mehler, A. H. 31, 59
Meister, A. 179, 181, 187, 216, 224
Mellgren, R. L. 242, 246, 249, 251, 266, 267
Melloni, E. 137, 144
Mentendiek, M. A. 31, 59
Menzel, H. 179, 187
Meredith, M. J. 176, 187
Merlevede, W 241–270
Mertus, A. E. 302, 316
Metcalf, B. W. 94, 101, 109, 113
Metz, W. 63, 66, 79, 85
Meuth, M. 370, 381
Meyers, C. A. 227, 230, 237
Meyers, S. M. 356, 379
Michell, R. H. 117, 126, 131
Michetti, M. 137, 144
Mickerns, K. W. 356, 378
Migeon, C. J. 355, 378
Mihich, E. 94, 102
Milbrath, J. R. 356, 379
Miller, D. M. 227, 230, 237
Minty, B. 165, 170
Milholland, R. J. 195, 207
Miscia, S. 274, 278, 282, 283
Mitchell, J. R. 185, 188, 189
Mitchell, T. 96, 103
Miyake, R. 195, 207
Miyamoto, T. 134, 143
Miyazaki, K. 225–237
Moffatt, J. G. 128, 131
Moghimzadeh, E. 63, 66, 74, 79, 85
Montejano, Y. 17–27
Montgomery, J. A. 11, 12, 14
Moore, E. C. 287, 288, 290, 293, 296, 297
Moore, M. A. 357, 359, 380
Mooren, P. G. 31, 34, 36, 59
Moran, R. G. 151, 152, 154, 161, 164, 170
Morikawa, M. 370, 382
Morita, T. 288, 290, 297
Moriyama, Y. 288, 290, 297
Morris, D. R. 96, 103, 241, 266
Morris, H. P. 287, 297, 336, 338–340, 342, 351, 352
Morrison, A. R. 117, 129, 131
Morrison, J. F. 3, 15
Moses, H. L. 225, 230, 232, 234, 236, 237
Motola, N. C. 107, 112
Moudgil, V. K. 204, 205, 207
Moyer, J. D. 107, 112
Muckel, C. 176, 177, 187
Muggia, F. M. 309, 316
Mulhern, A. I. 94, 102
Mullikin-Kilpatrick, D. 42, 60
Munro, J. B., III 291, 298
Murakami, K. 129, 131
Murayama, J. 288, 290, 297
Murphree, S. 287, 296
Murphy, B. E. P. 33, 60
Murphy, E. 129, 132
Murray, M. 319–333
Musser, J. H. 212, 223
Muziler, W. T. 327, 329, 333

Nagamine, Y. 45, 60
Nagasaki, T. 23, 27, 168, 170
Nagelschmidt, M. 5, 14
Naik, S. N. 357, 379
Nair, M. G. 157, 169
Nakagawa, H. 33, 60
Nakagawa, S. 202, 207
Nakamura, T. 48, 52, 61
Nakanishi, T. 191, 194, 206
Nakazawa, Y. 109, 113
Narayanan, V. L. 309, 316
Naruse,A. 176, 187
Natsumeda, Y. 215, 224, 296, 299, 335–352
Natuzzi, E. 98, 104
Needleman, P. 117, 129, 131
Négrel, R. 370, 382
Nelkin, B. D. 99, 104
Nelson, J. M. 302, 316
Neri, L. M. 278, 279, 283
Nesnow, S. C. 301, 316
Neufeld, E. J. 117, 131
Newitt, J. A. 356, 370, 371, 373, 374, 377, 379
Nicander, B. 294, 295, 298, 299
Nichol, C. A. 20, 27, 195, 207

Nierlich, D. P. 319, 320, 325, 326, 330, 332
Niijima, A. 66, 73, 84, 87
Nimec, Z. 147–150, 154
Nimmo, G. A. 262, 270
Niort, G. 357, 379
Nishioka, K. 95–97, 102, 103
Nishizuka, Y. 117, 131, 195, 207, 234, 237, 241, 266
Nixon, P. F. 3, 8, 14
Nixon, T. 370, 382
Nobin, A. 63, 66, 74, 79, 85
Noda, C. 48, 52, 61
Noguchi, H. 295, 299
Norin, E. 211, 212, 223
Norman, M. R. 202, 207
Noronha, J. M. 168, 170
Northrop, D. 6, 15
Novikoff, A. B. 370, 382
Novikoff, P. M. 370, 382
Nunn, J. F. 165, 170
Nutter, L. M. 287, 296
Nyce, J. W. 357, 358, 362, 365, 380

O'Brien, T. G. 97, 103, 195, 207
O'Ceallaigh, D. 98, 104
Ochi, K. 134, 143
O'Connor, T. 18, 27
Oertel, G. W. 356, 375, 378
Ognibene, O. 273, 282
Ohata, M. 63, 66, 79, 86
Ohisalo, J. J. 33, 59
Ohsawa, N. 191, 206
Oka, Y. 230, 237
Olah, E. 336, 340, 341, 344, 350–352
Oldham, R. K. 191, 207
Oliver, I. T. 46, 47, 60
Olson, J. W. 97, 104
Onda, H. 228, 237
Ookhtens, M. 185, 189
Orentreich, N. 355, 378
Ormstad, K. 211, 214, 223
Örning, L. 211, 212, 214, 217, 219, 220, 223, 224
Orrenius, S. 211, 223
Orth, D. N. 230, 237
Oshiro, G. 71, 75, 87
Ossenberg, F. W. 64, 87
Otto, R. 71, 72, 74, 87
Otvos, J. 319–333

Pairault, J. 370, 382
Pamucku, R. 345, 352
Pan, Y. C. N. 227, 230, 237
Pankaskie, M. 94, 102
Papa, S. 273–277, 282
Parameswaran, K. N. 165, 166, 170
Pardee, A. B. 295, 299
Paris, H. 249, 268
Parker, P. 260, 263, 269
Part, M. L. 96, 102
Pashko, L. L. 357–363, 365, 366, 369, 379, 380
Passamani, E. 287, 297
Pasternak, C. A. 272, 281
Paterson, S. J. 4, 14
Pato, M. D. 250, 257, 268, 269
Patrick, P. 3, 6, 15
Patterson, D. 320, 327, 329–333
Patterson, E. 97, 103
Paul, D. 96, 103
Paulus, H. 292, 298
Pearson, D. V. 357, 364, 365, 380
Pegg, A. E. 91–96, 100–103, 107–113, 241, 266
Pelech, S. 242, 243, 247, 253, 256, 257, 267
Perantoni, A. 360, 361, 363, 380
Perkins, J. P. 8, 15
Perry, J. 165, 170
Perry, S. T. 56, 61
Peterson, M. D. 288, 297
Phillips, A. W. 3, 6, 15
Pilkis, S. J. 243, 267
Pillwein, K. 335–352
Pinna, L. A. 241, 243, 257, 258, 260, 266, 267, 269
Piper, J. R. 148, 149, 154
Piper, P. J. 211, 220, 220
Pispa, J. P. 33, 59
Pleshkewych, A. 94, 102
Plummer, J. L. 176, 187
Pogson, C. I. 241, 243, 257, 266, 267
Polakis, S. E. 370, 382
Pollard, A. L. 158, 170
Pontremoli, S. 137, 144
Pope, L. 17–27
Porter, C. W. 94, 95, 102
Pösö, H. 93, 96–98, 101–104, 107, 112
Potter, D. W. 176, 187
Prajda, N. 296, 299, 336, 340, 341, 351, 352
Prakash, N. J. 94, 96–99, 101, 102, 104
Pratima, S. 152, 153, 155
Pratt, W. B. 204, 207
Prichard, M. M. L. 71, 87, 93, 101
Priest, D. G. 21, 27, 147–155, 157, 169
Prior, C. P. 278–280, 282
Pristupa, Z. B. 151, 154
Proost, C. 63, 86
Proper, J. A. 232, 237
Prpic, V. 48, 60

Pupons, A. 147, 148, 154
Pyke, S. 185, 188

Qi, D.-F. 241, 266
Quintanilha, A. 185, 188

Radika, K. 6, 15
Raina, A. 92, 96, 98, 101, 102, 104, 107, 112
Raineri, R. 356, 371, 375, 379
Rainsbury, R. 357, 379
Ramachandran, C. 255, 263, 269
Ramos-Martinez, J. I. 180, 188
Randall, R. L. 33, 60, 195, 207
Rapp, S. 211–213, 215, 217–221, 223
Raulf, M. 216, 224
Raynor, R. L. 241, 266
Reardon, M. A. 335–352
Reddy, G. P. V. 294, 295, 299
Reed, B. C. 370, 382
Reed, D. J. 176, 187
Reich, E. 45, 60
Reichard, P. 287, 288, 293–296, 298, 299
Reichman, M. 117–132
Reilley, F. D. 63, 66, 72, 79, 86, 87
Reinhart, P. H. 82, 88
Rennert, D. M. 93, 101
Rettenmier, C. W. 225, 236
Rey, D. A. 293, 298
Rhee, M. 147–155
Richardson, P. D. 72, 75, 83, 87, 88
Rinkema, L. E. 212, 223
Rixon, R. H. 291, 292, 295, 298
Rizer, R. L. 355, 378
Robel, P. 355, 378
Roberts, A. B. 227, 230, 232, 237
Roberts, B. J. 302, 316
Roberts, G. C. K. 8, 14
Roberts, J. J. 17, 27
Roche, N. S. 230, 237
Rodbard, D. 158, 169
Rodriquez-Segade, S. 180, 188
Roevens, P. 127, 131
Roguska, M. A. 289, 297
Rose, D. P. 356, 379
Rose, H. G. 272, 281
Rosebrough, N. J. 33, 60, 195, 207
Rosen, F. 195, 207
Rosen, O. M. 370, 382
Rosen, S. T. 99, 105
Rosenberger, A. L. 94, 102
Rosenfeld, P. J. 370, 382
Rosenfeld, R. S. 356, 379
Rosengren, E. 63, 66, 74, 79, 85
Rosengurt, E. 129, 131, 225, 236
Rosowsky, A. 151, 152, 154
Ross, J. S. 98, 104, 158–161, 170
Roth, B. 11, 12, 14
Rothblat, G. H. 272, 281
Rothrock, R. 56, 61
Rottman, A. J. 127, 131
Roussel, M. F. 225, 236
Routtenberg, A. 129, 131
Rouzer, C. A. 133–144
Rovito, R. J. 357, 359, 380
Rowe, P. B. 326, 333
Rubin, C. S. 370, 382
Rubin, E. H. 291, 292, 298
Rubin, R. P. 81, 88
Ruiz-Bravo, N. 34, 60
Rupniak, H. T. 96, 103
Russell, T. R. 370, 382
Russell, D. H. 92, 97, 98, 101, 104
Rwakunda, C. 357, 379

Sacca, R. 225, 236
Sacco, O. 137, 144
Safer, B. 249, 268
Sakakibara, R. 33, 39, 60
Sakamoto, Y. 176, 187
Sakauchi, N. 356, 379
Salamino, F. 137, 144
Samejima, K. 109, 113
Sammons, R. D. 327, 329, 333
Samson, M. 241, 266
Samuels, L. L. 148, 149, 154
Samuelsson, B. 133–144, 211, 222
Sanada, Y. 191, 206
Sando, J. J. 137, 143, 204, 207
Sannemann, J. 63–88
Sanno, Y. 54, 61
Sato, G. 228, 237
Sato, K. 357, 359, 380
Sato, M. 194, 206
Sato, S. 255, 268
Sauer, P. 326, 333
Sawyer, S. T. 195, 207
Scaaring, P. 63, 66, 79, 86
Scalabrino, G. 97, 104
Scanlon, K. J. 21, 27
Schaffer, W. T. 366, 367, 381
Schatzman, R. C. 241, 266
Schecter, P. 91, 93, 94, 96, 98, 99, 101, 102
Schendel, F. 319, 324, 330–333
Schenone, A. 94, 102
Scheuber, P. H. 211–213, 217–221, 223
Scheyerl, F. 212, 217, 219, 223
Schilsky, R. L. 157, 169
Schlender, K. K. 242, 251, 266, 267

Schneidereit, C. 54, 61
Scholz, R. 66, 67, 74, 87
Schoo, M. M. J. 151, 154
Schrimsher, J. L. 320, 327, 329–333,
Schuber, F. 93, 101
Schubert, C. 31–61
Schult, E. 180, 188
Schulze, E. 31–61
Schütz, G. 54, 61
Schwartz, A. G. 357–363, 365–367, 369, 379–381
Schwizer, R. W. 364, 365, 367, 381
Scovell, W. M. 18, 27
Scrimgeour, K. G. 20, 27, 151, 154
Sebolt, J. 336, 341, 343, 344, 351, 352
Seed, J. L. 360, 380
Seely, J. E. 93, 101
Seguin, E. B. 119, 131
Seidenfeld, J. 93, 101
Seiler, N. 93, 101
Sekar, M. C. 117–132
Selman, B. R. 320, 333
Selman-Reimer, S. 320, 333
Seydoux, J. 66, 74, 87
Seyfried, C. E. 96, 103
Shafman, T. 96, 103
Shane, B. 151, 152, 154, 155, 157, 161, 164, 169, 170
Shantz, L. M. 355–382
Sheffner, A. L. 185, 188
Shenolikar, S. 243, 267
Shepard, T. H., II 355–378
Shepherd, A. 366, 367, 381
Sherman, W. R. 118, 129, 132
Sherr, C. J. 225, 236
Sherwin, S. A. 191, 207
Shillis, J. L. 301–316
Shimazu, T. 63, 70, 82, 86, 88
Shimizu, N. 288, 290, 297
Shimizu, T. 134, 135, 137, 140, 143
Shiotani, T. 341, 352
Shipley, G. D. 225, 230, 234, 236
Shoji, M. 280, 283
Shuttleworth, K. 92, 101, 109, 113
Sidhu, R. S. 370, 382
Siedenstat, R. 365, 367, 381
Sies, H. 175–189
Siiteri, P. K. 355, 378
Silberman, S. R. 249, 268
Silver, M. 63, 66, 74, 86
Silverman, M. 168, 170
Silverstone, H. 357, 380
Simpson, C. L. 94, 102
Simsiman, R. C. 96, 98, 103, 104
Singh, J. 127, 132
Singh, V. B. 204, 205, 207
Singhal, R. L. 31, 59
Sirotnak, F. M. 148, 149, 154
Sjoerdsma, A. 91, 93, 94, 96, 98, 99, 101, 102, 104, 105
Skog, S. 291, 292, 298
Slaga, T. 96, 97, 103
Slavic, M. 99, 105
Sloan, J. S. 327, 330, 331, 333
Slotkin, T. A. 96, 102
Smalley, R. V. 191, 207
Smith, B. R. 176, 187
Smith, D. F. 212, 224
Smith, D. M. 227, 230, 237
Smith, J. A. 98, 104
Smith, J. M. 227, 230, 237
Smith, S. L. 3, 6, 15
Smith, W. L. 143
Snell, K. 34, 40, 42, 60
Snyder, S. H. 92, 101
Sobel, E. L. 357, 359, 380
Soberman, R. J. 136, 143
Sobero, A. F. 24, 27
Soboll, S. 175, 176, 186
Šonka, J. 356, 363, 379, 381
Sparatore, B. 137, 144
Sparmann, G. 31–61
Spector, T. 8, 15
Spicer, C. C. 356, 379
Spiegelman, B. M. 370, 382
Sporn, M. B. 225, 230, 232, 236, 237
Spyrou, G. 295, 299
Srivastava, S. K. 31, 59
Stadtman, E. R. 186, 189
Stamm, N. B. 31, 59
Stamm, W. E. 13, 15
Stammers, D. K. 12, 14
Stanley, E. R. 225, 236
Staś, J. 356, 379
Stauber, P. 356, 379
Stehle, T. 182, 188
Stein, S. 227, 230, 237
Steinetz, B. 184, 188
Steinhoff, M. M. 134, 143
Stern, D. F. 230, 237
Stern, E. 356, 379
Steward, A. A. 243, 254, 258, 262, 267–270
Stewart, H. J. 356, 379
Stokstad, E. L. R. 165, 168, 170, 171
Stolowich, N. J. 95, 102
Stone, D. 3, 4, 6, 14, 15
Stone, S. R. 3, 15
Strada, S. J. 262, 269
Strain, G. W. 356, 379
Stratford, C. A. 204, 207
Streckfuss, A. 152, 154
Stroobant, P. 225, 236
Strulik, H. 64, 73–75, 86, 88

Stubbe, J. 319–333
Stubbs, M. 339, 351
Student, A. K. 370, 382
Su, H. 280, 283
Suda, M. 33, 60
Sugiura, K. 315, 316
Sugiura, M. 96, 103
Sulis, E. 357, 379
Summer, K. H. 179, 187
Sun, F. F. 134, 143
Sunkara, P. S. 94–99, 102–104
Sur, P. 21, 27
Suresh, M. R. 23, 27
Swern, D. 357, 358, 362, 363, 365, 379

Tabor, C. W. 91–93, 95, 100, 241, 266
Tabor, H. 91–93, 95, 100, 241, 266
Tagliaferro, A. R. 366, 381
Takahashi, K. 176, 187
Takai, Y. 195, 207, 241, 266
Takatani, O. 356, 379
Takeda, E. 287, 297, 336, 340, 344, 351, 352
Takeda, M. 249, 268
Takigawa, M. 98, 104
Talalay, P. 355–382
Tallant, E. A. 254, 262, 268
Tamura, S. 242, 249, 266
Tanaka, K. 194, 206
Tanaka, T. 54, 61
Tanaka, Y. 195, 207
Tang, K.-C. 95, 102, 108, 110–113
Taniguchi, K. 134, 143
Tannen, R. H. 357, 358, 365, 367, 369, 380, 381
Tannenbaum, A. 357, 380
Tansik, R. L. 3–15
Tardif, C. 93, 99, 101, 104
Tata, J. R. 278, 282
Tate, S. S. 216, 224
Tateishi, N. 176, 187
Taylor, R. T. 159, 170
Taylor, W. M. 82, 88
Temple, C., Jr. 11, 12, 14
Tener, G. M. 128, 131
Thamavit, W. 357, 359, 380
Thams, P. 241, 266
Thao, T. 181, 188
Thelander, L. 287, 288, 290–293, 296–298
Thiel, A. 356, 379
Thomas, A. P. 117, 132
Thomas, J. P. 177, 178, 187
Thompson, E. B. 202, 207
Thysseril, T. J. 242, 251, 267
Toda, M. 211, 223
Todaro, G. J. 225, 236
Tomihara, Y. 191, 192, 206
Tomino, I. 191, 206
Tomita, Y. 194, 206
Tomkins, G. M. 195, 207
Tomomura, A. 48, 52, 61
Tomsová, Z. 356, 379
Tonks, N. K. 258, 269
Tran, T. 181, 188
Tribukait, B. 291, 292, 298
Trush, M. A. 360, 380
Tscherning, K. 355–378
Tsuda, H. 357, 359, 380
Tsuda, T. 191, 206
Tsuiki, S. 242, 249, 266
Tucker, R. F. 225, 230, 232, 234, 236, 237
Tung, H. Y. L. 242, 243, 247, 248, 250, 253, 257, 267
Turk, J. 117, 129, 131, 132
Turner, M. K. 287, 297
Turner, R. S. 241, 266, 271, 272, 280, 281, 283
Tzeng, D. Y. 336, 340, 341, 344, 351, 352

Uehara, N. 211, 214, 223
Uemura, D. 192, 206
Ullman, B. 294, 298
Ungvary, G. 63, 66, 71, 79, 86, 87
Usami, M. 82, 88
Usui, H. 249, 268
Uyeda, K. 33, 39, 60

VanBelle, H. 254, 268
VanLancker, J. L. 288, 297
Vandenheede, J. R. 242, 243, 248, 249, 256, 260, 262, 263, 266, 268, 269
Vande-Wiele, R. 355, 378
Vanoni, M. A. 165, 170
VanSchaftingen, E. 33, 60
Varga, B. 71, 87
Veech, R. L. 366, 367, 381
Venditti, J. M. 309, 316
Verma, A. K. 97, 98, 103, 104
Verwilghen, R. L. 357, 379
Vevert, J. P. 94, 101, 109, 113
Vickers, P. J. 151, 154
Villar-Palasi, C. 137, 143
Villson, J. K. V. 345, 352
Vitale, M. 278, 279, 283
Vitková, M. 356, 379
Vitols, K. S, 17–27
Vogelman, J. H. 355, 378
Volkenant, M. E. 230, 237

Volz, K. W. 12, 14
Von der Ahe, D. 54, 61

Waddell, D. 294, 298
Waelkens, E. 241–270
Wagner, J. 99, 105
Wahlländer, A. 175, 176, 186
Wakefield, L. M. 230, 237
Walford, R. L. 365, 369, 381
Walker, R. 40, 59, 60
Walsh, D. A. 255, 257, 263, 269
Wang, D. Y. 356, 379
Wang, J. L. 225, 232, 234, 236
Wang, T. 94, 102
Watanabe, I. 191, 192, 206
Waterfield, M. D. 225, 236
Watson, A. A. 301, 316
Watts, C. 46, 60
Waydhas, C. 175, 176, 186
Webb, E. C. 342, 352
Weber, G. 3, 15, 31, 59, 98, 104, 215, 224, 287, 296, 297, 299, 302, 316, 335–352
Weber, W. W. 220, 224
Weckbecker, G. 211–224
Weeks, C. 96, 103
Wehrli, S. 319–333
Weindruch, R. 365, 369, 381
Weiss, B. 254, 268
Weiss, E. 31–61
Weiss, P. 225, 234, 236
Weissbach, H. 159, 170
Weissman, R. M. 96, 103
Weng, D. E. 356, 370, 371, 373, 374, 377, 379
Werth, D. K. 249, 268
Westermark, B. 225, 234, 236
Whelan, C. J. 211, 223
Whipple, J. H. 137, 143
Whitcomb, J. M. 357, 358, 380
White, A. 202, 207
Whitehead, V. M. 157, 169
Whitfield, J. F. 288, 290–292, 295, 297, 298
Whitford, T. W. 293, 298
Wideman, J. 227, 230, 237
Widnell, C. C. 278, 282
Wiener, H. 97, 103
Wilker, D. 211–213, 217–221, 223
Williams, J. C. 341, 352
Williams, J. R. 357, 359, 380
Williams, L. H. 370, 382
Williams-Ashman, H. G. 91–94, 98, 100–102, 104, 107, 112, 241, 263, 264, 266, 270
Williamson, J. R. 117, 132
Wilson, D. B. 117–119, 129, 131, 132
Wilson, R. W. 107, 112
Wilson, S. E. 242, 251, 266, 267
Wise, L. S. 370, 382
Withrington, P. G. 72, 75, 83, 87, 88
Wolcke, U. 301, 316
Wolf, B. A. 129, 132
Wolfenden, R. 108, 113
Wolska-Mitaszko, B. 4, 15
Wong, C. 63, 64, 66, 70, 74, 86
Woods, R. A. 320, 332
Wright, D. A. 95, 102
Wright, G. 211, 223
Wright, J. A. 288–290, 297
Wright, R. S. 128, 131
Wyngaarden, J. B. 326, 333

Yalowich, J. C. 157, 169
Yamaguchi, N. 66, 75, 87
Yamamoto, M. 241, 266
Yamamoto, S. 134, 143
Yamamura, H. 241, 266
Yamashita, J. 225–237
Yamashita, N. 226–229, 236
Yang, P. 96, 98, 103, 104
Yang, S.-D. 242, 243, 248, 249, 254, 256, 260, 262, 263, 266, 268, 269
Yano, K. 225–237
Yen, T. Y. 357, 364, 365, 380
Yeoh, G. C. T. 46, 47, 60
Yoshikawa, J. 228, 237
Yoshimoto, T. 134, 143
Yosikawa, K. 249, 268
Youdale, T. 288, 290–292, 295, 297, 298
Young, M. 327, 329, 333
Yun-Tso, J. 320, 333
Yuspa, S. H. 97, 103

Zaks, W. J. 137, 143
Zalkin, H. 320, 333
Zbarsky, I. B. 271, 281
Zeitler, P. 129, 132
Zeltzman, M. 99, 105
Zhen, Y.-S. 335–352
Ziegler, D. M. 175, 176, 179, 186
Zini, N. 273, 282
Zisk, J. 366, 367, 381
Zumoff, B. 356, 379

SUBJECT INDEX

A23187 on GSH release 183
N-Acetyl LTE_4 (LTE_4 NAc)
  catabolic deactivation of leukotrienes and 211
  in bile 218, 221
  in mercapturic acid pathway 212
Acetylcholine
  on arachidonoyl residues 125
  on prostaglandins 125, 130
Acivicin
  inhibition of γ-glutamyltransferase 215
  synergistic action with dipyridamole 345
Adenine phosphoribosyltransferase (APRT, EC 2.4.2.7)
  in liver and hepatoma 3924A 340
    kinetic parameters 341
    substrate levels 342
  in purine salvage 337
S-Adenosyl-1,12-diamino-3-thio-9-azadodecane (AdoDATAD)
  inhibition of aminopropyltransferases 110
  on cell polyamines 110–112
  structure 109
  synthesis 108
S-Adenosyl-1,8-diamino-3-thiooctane (AdoDATO)
  dcAdoMet and 111
  inhibition of aminopropyltransferases 110
  on cell polyamines 110–112
  structure 109
  synthesis 108
Adenosylhomocysteine hydrolase (EC 3.3.1.1) and folate metabolism 160
S-Adenosylmethionine (AdoMet)
  analogs 94
  decarboxylation 92
  folate pools and 168
  methylenetetrahydrofolate reductase and 165
decarboxylated *S*-Adenosylmethionine (dcAdoMet) 109
  in AdoDATO-treated cells 111
  polyamine biosynthesis and 92
S-Adenosylmethionine decarboxylase (AdoMet DC, EC 4.1.1.50)
  AdoDATO on 111
  DFMO on 94
  polyamine biosynthesis and 92, 93
  promoting agents on 97
Adenosylmethionine-dependent methyl transferases and folate metabolism 160
Adenosylmethionine synthetase (EC 2.5.1.6) and folate metabolism 160
S-Adenosyl-(±)-2-methyl methionine on Spm levels 94
Adenylosuccinate synthase compared with salvage enzyme 337
Adjuvant arthritis and GSH 184
Adipocytes
  diamide on 179
  inhibition of formation by DHEA 368–378
ADP reductase (EC 1.17.4.1)
  allosteric effectors 293, 294
  DMF on 288
  DMSO on 288
  from L cells 288, 289
  from MC-3-3 cells 289
  hydroxyurea on 288, 289
  IMPY on 288
  pyridoxal phosphate on 288, 289
Adrenalectomized rats
  ODC induction in 197–200
  TAT induction in 196–202
Adrenalectomy (Adx) rat
  mortality following 35
  on circulating glucocorticoids 35
  on enzyme induction 34, 40
    DOC and 36
  on PFK2 40
Adrenaline regulation 66, 84
Adrenergic system, rat liver
  alpha
    age-dependent prazosin binding 48–50
    components of 47
    developmental alterations 47–51
    model for 44
    PFK2 and GLU control 43
    SDH control 43, 44
  beta-dominance and glucagon 42
  enzyme induction and glucagon 40–47
Aerobacter aerogenes GAR synthetase 330
Aflatoxin
  mitogenesis DHEA on 363, 364
  on rat liver cells, DHEA and 360
Aging in rodents, DHEA on 368, 369
AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) transformylase (EC 2.1.2.3) and methotrexate 158

Alpha-blocking agent (phentolamine) on liver metabolism 66, 68, 85
α-Amanitin on RNA synthesis, PS on 275, 277
Amidophosphoribosyltransferase (EC 2.4.2.14)
  compared with salvage enzyme 337
  in liver and hepatoma 3924A
    kinetic parameters 341
    substrate levels 342
Aminoimidazole ribonucleotide synthetase (AIR synthetase, EC 6.3.3.1)
  from chicken liver 327, 328
  from various sources 330
  GAR synthetase and 320
  homologies 330, 331
  M_r 330
  N-terminal sequences 331
  purification 327, 328
Aminopeptidase (microsomal) (EC 3.4.11.2)
  compared with LTD_4 dipeptidase 216
Aminophylline on SDH induction 42
Aminopterin-aqua Cisplatin complex 19, 20
Ammonia uptake control in liver 66–68
cAMP in liver 80
cAMP-dependent protein kinase
  inhibitor 1 phosphorylation and 262
  substrate requirement 260
Amphotericin B
  on hepatoma cells in log and plateau phase 348
  on human colon cancer cells in log and plateau phase 349
  on inhibitory action of dipyridamole on nucleoside incorporation 348
  on sensitivity to dipyridamole in hepatoma cells 349
  on sensitivity to dipyridamole in human colon cancer cells 349
  structure 348
Amylase release, inhibition of 128
5α-Androstane-3β,17β-diol on preadipocyte differentiation and G6PD 375
5β-Androstane-3α,17β-diol on preadipocyte differentiation and G6PD 375
5β-Androstane-3β,17β-diol on preadipocyte differentiation and G6PD 375
5α-Androstane-3,17-dione on preadipocyte differentiation and G6PD 375
5β-Androstane-3,17-dione on preadipocyte differentiation and G6PD 375
5-Androstene-3β,17β-diol on preadipocyte differentiation and G6PD 375
4-Androstene-3,17-dione on preadipocyte differentiation and G6PD 375
Androsterone (3α-hydroxy-5α-androstan-17-one)
  isolation and characterization 355
  on preadipocyte differentiation and G6PD 375
Angiotensin on GSH release 183
Anticarcinogenesis, DHEA and 356
Antifolates, folylpolyglutamate synthetase affinity 161
Aortic muscle polycation-modulated phosphatase 257
  subunits 248
Arachidonate
  in phosphoinositide signalling system 118
  release from minilobules 123
    functional significance 129
    cGMP formation and 126
Arachidonic acid
  labelled minilobules 123
  5-lipoxygenase and 133, 136
  release RHC 80267 and 124
ATP on 5-lipoxygenase 136, 138
ATP, Mg-dependent protein phosphatase *see* Protein phosphatase
ATP : D-fructose 6-phosphate 2-phosphotransferase *see* Phosphofructokinase 2
dATP inhibition of ribonucleotide reductase 294, 295
Autoimmunity in rodents, DHEA on 368, 369
5-Azacytidine on enzyme induction
  in Adx rats 58
  in fetal rat liver 56
  in suckling rat liver 57

Bestatin on peptidase activities 216
Beta-blocking agent (propanolol) on liver metabolism 66, 68, 85
Biliary taurocholate release, diamide on 182
Biotin on preadipocyte differentiation 370
Bovine kidney MDBK cells ribonucleotide reductase M2 subunit 291, 292
16α-Bromoepiandrosterone (16α-bromo-3β-hydroxy-5α-androstan-17-one, 16α-Br-E)
  inhibition of differentiation 361, 371–375
    reversal by ribonucleosides 376, 377
  on DNA synthesis 362–364
  on G6PD 375
  superoxide generation and 360
t-Butyl hydroperoxide
  cell thiol redox state and 178
  stimulation of pentose phosphate pathway 179–181

Cadaverine stimulation of PCS phosphatase 251

Caerulein stimulation of minilobules 123
Calcium
  on GSH release 183, 184
  5-lipoxygenase dependence 136–139, 141
  release from endoplasmic reticulum 129
Cancer and DHEA 356–364
Candida albicans DHFR
  initial velocity analysis 5, 6
  negative cooperativity 7, 13
  preparation 4
  proteolysis on 7
Canrenoate on SDH activity 37, 38
Carbamoyl-phosphate synthase II (EC 6.3.5.5) compared with salvage enzyme 337
Carbamylcholine stimulation of minilobules 118, 126
Carboxyfluorescein (6-CF) uptake into nucleoplasm 273
Carcinogenesis and polyamine metabolism 97
Carcinomas
  DHEA and 355–378
  human
    epidermoid A431 226
    HeLa 226, 360, 361
    lung A549 303
    lung small cell 99
    mammary 356
    mammary MCF-7 158, 303
    mammary MX1 307, 309
  mouse
    Ehrlich ascites 96, 98, 290–292
    Lewis lung 303
    mammary 16/c 303, 308, 309
Catecholamine suppression of glucagon effect 42, 44
CDP reductase (EC 1.17.4.1)
  allosteric effectors 293, 294
  blue dextran on 288
  compared with salvage enzymes 337
  from CHO cells 289, 290
  from L cells 289, 290
  from MC-3-3 cells 289
  from regenerating rat liver 288
  from Yoshida ascites sarcoma 288
  hydroxyurea on 288, 289
  in liver and hepatoma 3924A
    kinetic parameters 342, 343
    substrate levels 343, 344
  inhibition 290
  pyridoxal phosphate on 288, 289
  Triton X100 on 288
Cell cycle
  polyamine levels and 96
  ribonucleotide reductase in 287, 291, 292
Chemotherapy
  amphotericin B with dipyridamole 350, 351
  antifolate 158
  DFMO clinical studies 99
  experimental, guanine-7-oxide 301–316
  glucocorticoid 202
  platinum compounds 17
  polyamine inhibitor 91
  salvage pathways as targets 335–351
Chicken liver
  AIR synthetase 328, 330
  GAR synthetase 329, 330
Chinese hamster CHO cells ribonucleotide reductase levels in 289, 290
Cholesteryl-14-methylexadecanoate (CMH) on transcription 273, 274
Chromatin
  fibers histone removal and 276, 280
  fractionation 279
  lipids in 271
Cisplatin (cis-diamminedichloroplatinum-II)
  cytotoxicity 24
  in chemotherapy 17
  on folate compounds *in vivo* 20–24
  structure 18
Cobalamin-dependent methionine synthase (EC 2.1.1.13) and methyltetrahydropteroylglutamate 165, 166
Colony-stimulating factor (CSF-1) 225
Concanavalin A mitogenesis DHEA on 363, 364
Conjugase *see* γ-Glutamyl hydrolase
Corticosterone induction of TAT 202
CTP synthase (EC 6.3.4.2)
  compared with salvage enzyme 337
  in liver and hepatoma 3924A
    kinetic parameters 342, 343
    substrate levels 343, 344
Cysteinyl leukotrienes (*see also* individual compounds)
  elimination pattern in monkey 219, 220
  endogenous in primates 220
  endogenous in rat 218
  enterohepatic circulation, significance of 219, 222
  metabolites hepatobiliary elimination in rat 217
  metabolites in bile and urine 213, 220
  physiological roles 211
Cytidine kinase (EC 2.7.1.48)
  in liver and hepatoma 3924A
    kinetic parameters 342, 343
    substrate levels 343, 344
  in pyrimidine salvage 337

3-Deazaguanine
antitumor activity 308, 309
structure 310
Decarboxylated *S*-adenosylmethionine *see* dcAdoMet
Dehydroepiandrosterone (3β-hydroxy-5-androsten-17-one, DHEA)
on growth, differentiation and carcinogenesis 355–378
antidiabetic action in mice 367
cancer and 356–364
cell growth and 360
distribution in man 355
human mammary cancer and 356
inhibition of G6PD 356, 375
inhibition of preadipocyte differentiation 368–378
mouse tumors and 357–360
on aflatoxin effects 360
on aging 368
on autoimmune processes 368
on cell transformation 363, 364
on DMBA metabolism 361
on food intake 365, 366
on mitogenesis 361–364
on weight gain of mice 365
on weight gain of rats 366
physiological and pharmacological effects 356
rat tumors and 359
superoxide generation and 360
Dehydroepiandrosterone-3-sulfate on preadipocyte differentiation and G6PD 375
Deinhibitor protein
dephosphorylation 243
regulation by PCS_H phosphatases 260, 263
regulation of protein phosphatase 262
substrate for PCS phosphatases 251, 257
Deoxycorticosterone (DOC)
glucocorticoids and 36, 37
on enzyme levels in Adx rats 36
on enzyme levels in normal rats 37, 38
Deoxycytidine kinase (EC 2.7.1.74)
in liver and hepatoma 3924A
kinetic parameters 342, 343
substrate levels 343, 344
in pyrimidine salvage 337
2′-Deoxyguanosine and guanosine-7-oxide 305
5′-Deoxy-5′-methylthioadenosine (MTA)
inhibition of aminopropyltransferases 107
5′-Deoxy-5′-methylthiotubericidin (MTT)
inhibition of aminopropyltransferases 107
Dexamethasone
enzyme induction, dose dependence 200
induction of ODC 197
induction of TAT 196–200, 202, 204
on preadipocyte differentiation 370, 371, 373
on renal GLU 55
on SDH in Adx rats 36, 38
on SDH in Adx,Gnx rats 52
on SDH, TAT and PFK2 in suckling rats 53, 56, 57
Diabetes in mice
DHEA protection 367
17β-estradiol protection 367
progesterone protection 367
Diacylglycerol (DG)
activation of protein kinase C 117
arachidonate metabolism and 123
formation 117
in phosphoinositide signalling system 118, 130
levels, RHC 80267 on 124
Diamide oxidation of thiols 179
Diamine oxidase (EC 1.4.3.6) and polyamine biosynthesis 92, 93
Diaminobenzylpyrimidines
kinetic and binding constants 11
structures 9
cis-Diamminediaquaplatinum(II)-ion *see also* Cisplatin
structure 18
with folates 19, 20
with methotrexate 22
with tetrahydrofolate 18–20, 25
cis-Diamminedichloroplatinum(II) *see* Cisplatin
Dibutyryl cAMP on TAT induction 45, 46
Diethylnitrosamine carcinogenesis in rat, DHEA on 359, 360
D,L-α-Difluoromethylornithine (DFMO)
clinical chemotherapy 99
inhibition of ODC 93–96, 98, 109
on cell polyamines 110–112
on tumor cell growth 98, 99
Diglyceride kinase inhibitor R59022 and cGMP formation 126, 127
Diglyceride lipase (EC 3.1.1.34)
inhibitor RHC80267 130
on glycerols 124
on cGMP 126
on inositol monophosphate 128
on pancreatic exocrine cells 123
Dihydrofolate (FH_2) 4
substrate inhibition 6
substrate protection 7
Dihydrofolate reductase (5,6,7,8-tetrahydrofolate $NADP^+$

oxidoreductase, DHFR, EC 1.5.1.3)
inhibition by methotrexate 157
inhibition by platinum tetrahydrofolate 24, 25
substrate-inhibitor cooperative reactions 3–14
assay 4
complexes, structures 13
complexes, trimethoprim binding 11
equilibrium dialysis 4
from bovine liver 11, 12
from *C. albicans* 4
from *E. coli* 11, 12
from mouse lymphoma 11, 12
from *N. gonorrhoeae* 4
from *S. cerevisiae* 4
from *S. faecium* 11, 12
inhibitors 4
negative cooperativity 3, 6–8, 13
Ping-Pong mechanism and 6
positive cooperativity 3, 6
preparation 4
random Bi–Bi reaction mechanism 3, 7
Dihydroxy-di-*n*-propylnitrosamine carcinogenesis in rat, DHEA on 359, 360
7,12-Dimethylbenz(a)anthracene (DMBA) binding and metabolism, DHEA on 361
carcinogenesis in mouse, DHEA on 358
Dimethylformamide (DMF) on nucleotide reductases 288
1,2-Dimethylhydrazine carcinogenesis in mouse, DHEA on 358
Dimethylsulfoxide (DMSO) on nucleotide reductases 288
1,2-racemic Dioctanoyl glycerol (1,2-DG)
GPA activity 192, 194
hormonal specificity 201
on dexamethasone induced ODC 198–200
on dexamethasone induced TAT 195, 196, 198–200
on L5178Y tumor growth 202, 203
1,2-Dioleoyl-racemic-glycerol on L5178Y tumor growth 202, 203
Dipyridamole
cell phase dependency of action 345, 347
cytotoxic action in hepatoma 3924A cells 344, 349
on concentrations of GTP, ATP, UTP and CTP 345
on nucleoside incorporation 344, 345, 347
on salvage nucleoside transport 335
on uridine and thymidine incorporation 345
sensitivity of log and plateau phase hepatoma cells 345, 346
synergism with acivicin 345
synergism with amphotericin B 349
Dithioerythritol on pentose phosphate pathway 179, 180
Divalent cations on PCS phosphatases 253
DNA synthesis and ribonucleotide channeling 295
Dog kidney cell line MDCK 226
EGI on 230
Drosophila melanogaster
GAR and AIR synthetases 330, 331
multifunctional polypeptide from 327

EGTA on GSH release 183
Ehrlich cells *see* Mouse, Ehrlich cells
Eicosanoids in phosphoinositide signalling system 118
Embryonic fibroblasts diamide on 179
Enzymic differentiation
hormones in 31–59
role of placenta 47
Epiandrosterone (3β-hydroxy-5α-androstan-17-one)
inhibition of G6PD 361, 375
on preadipocyte differentiation 375
Epidermal growth factor (EGF)
biological activity 194, 196
GPA activity 192, 194
growth control and 225, 230
on dexamethasone induced TAT 195, 196, 198, 204
Epinephrine on GDH synthesis 43
Epithelial growth inhibitors (EGIs) 226, 235
human 230, 236
rat 229, 232, 233, 235, 236
Epstein-Barr virus (EBV) induced mitogenesis DHEA on 363, 364
Erythrocyte
diamide on 179
thiol redox perturbance 178
Escherichia coli
catabolite activator protein 45
DHFR 11–13
diamide on 179
GAR and AIR synthetases 330, 331
ribonucleotide reductase properties 287
17β-Estradiol
antidiabetic action 367
induction of G6PDH 202
on GLU in rat kidney 55
on preadipocyte differentiation and G6PD 375
on SDH in Adx,Gnx rats 52
on SDH, TAT and PFK2 in suckling rats 53

Fatty acid
oxidation 133
synthesis and preadipocyte differentiation 370
Folate
Cisplatin interaction *in vivo* 20–24
coenzymes as Cisplatin targets 17
compounds, separation by HPLC 20, 21, 23
-dependent enzymes 157–169
folylpolyglutamate inhibitor affinities 161
folylpolyglutamate substrates 168
metabolic pathways and 160
methionine synthase 158
methylene tetrahydrofolate dehydrogenase 159, 160
methylene tetrahydrofolate reductase 158
serine hydroxymethyltransferase 159
thymidylate synthase 158
-platinum complexes 19, 20
pools
Cisplatin on 20, 23
methotrexate on 151–153, 157
plasma folate derivatives in 164–169
transport inhibition by platinum tetrahydrofolate 24
Folylpolyglutamate synthetase (FPGS, EC 6.3.2.17)
affinity of antifolates 161
assay 148
in hepatocytes and hepatoma cells 150
in stationary and dividing cells 150, 151
methotrexate polyglutamination 157
polyglutamate formation and 147
Folypolyglutamates
folate-dependent enzymes and 157–169
relative affinities 162
inhibitors, enzyme affinities 161
on polyglutamylation 151
Formylglycinamide ribonucleotide amidotransferase (FGAM amidotransferase) (EC 6.3.5.3)
substrates 324
5-Formyltetrahydrofolate-aquaCisplatin complex 19, 20
Friend cell *see* Mouse erythroleukemia (MEL)
Fructose 2,6-bisphosphate in liver 80

Gamma-aminobutyrate (GABA) from putrescine 92, 93
GAR transformylase (EC 2.1.2.2) and antifolate drugs 158
GDP reductase
allosteric effectors 293, 294
in CHO cells 289, 290
in L cells 288, 289
β-Globin RNA synthesis, phospholipids on 275, 277
Glucagon
α-adrenergic system antagonism 42, 45
catecholamines and 44
induction of SDH in Adx,Gnx rats 52
induction of TAT 201
induction (precocious) of TAT and SDH 34
interaction with adrenergic system in induction 40–47
on glucose and lactate 67, 69
on glucose in blood 49, 51
on GSH release 183
on SDH and TAT with phentolamine 41
regulation by nervous system 66
Glucocorticoid
action biomodulators 191–206
potency amplifiers (GPAs) 192
inhibition of 203, 204
in vitro assays 194
in vivo assays 193
on glucocorticoid action 205
on L5178Y lymphoblasts 194, 195, 202
on TAT induction 196–202
receptors, nature of 204, 205
sensitivity amplifiers (GSAs) 191
on glucocorticoid action 205
pseudouridyl derivatives 191, 193
structures 193
Glucocorticoids
circulating, after adrenalectomy 34, 35
competence, developmental changes 54–58
DOC and 36, 37
Glucose
homeostasis network 84
output control in liver 66–68, 73–81
Glucose-6-phosphate dehydrogenase (G6PD, EC 1.1.1.49)
diabetes and 367
deficiency and cancer risk 357
GSSG on 180
inhibition by DHEA 356, 367
inhibition on cell growth 360, 361
inhibition reversal by ribonucleosides 376, 377
inhibition, steroid structure and 374, 375
inhibition, TdR incorporation and 361, 364
β-Glucosidase (GLU, EC 3.2.1.21) rat renal
α-adrenergic control 32, 43
Adx on 36, 39

assay 33
at weaning 37
dexamethasone induction, age on 55
Glutamine output regulation in liver 68
γ-Glutamylcarboxypeptidase (γ-glutamyl hydrolase, conjugase, EC 3.4.22.12)
assay 148
in folate analysis 22
in hepatocytes and hepatoma cells 150
methotrexate on 152, 153
polyglutamate breakdown and 147
γ-Glutamyltransferase (EC 2.3.2.2)
inhibition by acivicin 215
inhibition, on hepatoma cells 215
LTC_4 to LTD_4 reaction 212
Glutathione (GSH)
assay 177
efflux, hormonal stimulation 181–185
adjuvant arthritis and 184, 185
muscular activity on 185
GSSG transport 181
protein binding 185
redox state 175
system GSH/GSSG 176, 177
Glutathione peroxidase (EC 1.11.1.9)
substrate 178, 179
thiol redox state and 176
Glutathione transferase (EC 2.5.1.18) 176, 177
Glycerol release from minilobules 123
RHC80267 and 124
Glycerol-3-phosphate dehydrogenase (EC 1.1.1.8) levels in differentiation to adipocytes 370, 371, 373, 374, 377
Glycineamide ribonucleotide (GAR)
formation 319
synthesis 320
Glycineamide ribonucleotide synthetase (GAR synthetase, EC 6.3.4.13)
assay 320, 321
from *E. coli* 325, 327
from various sources 330
β-GAR substrate 324
homologies 330, 331
isolation 327, 329
M_r 323, 327, 330
N-terminal sequences 331
PRA transfer to 326
purification 321–323
reaction catalyzed 319, 324
Glycineamide ribonucleotide transformylase (GAR transformylase, EC 2.1.2.2)
from *D. melanogaster* 327
in trifunctional polypeptide 320
substrates 324
Glycogen metabolism, regulation 261, 262
Glycogen phosphorylase (EC 2.4.1.1) in liver 80, 85
Glycogen synthase I (EC 2.4.1.11) in liver 80, 85
cGMP
formation in minilobules 126
regulation 118
Gonorrhoeae possible synergistic therapy 13
Growth
control, inhibitors and 234
factors 225
in human platelets 230
possible mechanisms 234
hormone on preadipocyte differentiation 370
inhibitors 225–236
acetic acid on 234, 236
assay 227
extraction 227
from rabbit serum 229
from rat tumor tissues 233
from various rat tissues 232, 233, 235
in human platelets 230
in rat serum 229
possible role in growth control 234
secretion from BRL and RSV-BRL cells 233, 235
Guanine deaminase (EC 3.5.4.3) in rat hepatoma 3924A 340
Guanine nucleotide binding protein (N-protein) in α-adrenergic system 47
Guanine-7-oxide (7-hydroxyguanine) 301–316
cytotoxicity to cultured cells 303
guanosine protection 304–306
experimental chemotherapy 306–308
antipurines compared 308, 309
isolation 301
mechanism of action 308, 310
metabolic products 313, 314
on DNA synthesis 311
on protein synthesis 312
on ribonucleotide pools 312, 313
on RNA synthesis 311
structure 302
Guanine phosphoribosyltransferase (GPRT, EC 2.4.2.8)
in liver and hepatoma 3924A
kinetic parameters 341
substrate levels 342
in purine salvage 337
Guanine protection against guanine-7-oxide 304, 305
Guanosine-3′-diphosphate GPA activity 192

Guanosine-7-oxide 5′-triphosphate
formation in sensitive cells 314, 315
from guanine-7-oxide metabolism 313
Guanosine protection against
guanine-7-oxide 304–306
Guanyl-5′-yl imidodiphosphate on prazosin
displacement in liver 49, 50
Guinea pig
brain, acetylcholine and 125
liver, perfused 79, 85

H7(1-(5-isoquinolinesulfonyl)-2-
methylpiperizine) inhibition of TAT
induction 203–205
Hamster V79 cells diamide on 179
Heart
diamide on 179
thiol redox state perturbance 178
Heparin on protein phosphatase 255
Hepatic nerve stimulation
arterial and portal compared 74, 75
extrahepatocellular mechanism 76, 78
hemodynamic effects 71, 77, 84
parasympathetic actions 68, 69, 71
on glucose release 70
physiological relevance 72, 73
sympathetic actions 66, 71
on ammonia uptake 67
on glucose balance 67, 73
on ketone bodies 67
on lactate balance 67, 73
on noradrenaline 67, 79
on oxygen uptake 67
on portal flow 67
on urea production 67
scheme 65
Histone
H_1
on PCS protein phosphatase 249–251,
254, 257
removal, PS on 267, 277
H_3 accessibility PS on 279, 281
lipid interaction 273
pattern changes 276
Hormonal stimulation of GSH
efflux 181–185
Hormones in enzymic differentiation 31–59
HPETE *see* Hydroperoxyeicosatraenoic acid
HTC cells inhibition of polyamine
biosynthesis in 110
Human
acute pancreatitis, biliary LTE_4
in 220–222
blood platelets
growth inhibitor (EGI) 230, 231
TGFβ 230, 231
colon carcinoma HCT-8 cells, guanine-7-
oxide cytotoxicity 303
colon carcinoma HT-29 cells dipyridamole
and amphotericin on 349
embryo skin tissue YH-1 cells 226
transformed B-32 cells 226
epidermal carcinoma A431 226
EGI on 230
HeLa
cell lines DHEA on 360, 361
S3 line 226
hepatoma, G6PD levels and 357
liver, methotrexate on 152
lung carcinoma A549 guanine-7-oxide
cytotoxicity 303
lung carcinoma, small cell DFMO on 99
lymphoblast WI-L2 cells, guanine-7-oxide
cytotoxicity 303
on ribonucleotide pools 313
5′-triphosphate formation in 315
lymphoblast WI-L2/TG1 cells
antipurine resistance 304
guanine-7-oxide cytotoxicity 303
mammary cancer DHEA levels and 356
mammary cancer MCF-7 cells
folate pool 158
guanine-7-oxide cytotoxicity 303
mammary cancer MX-1
antipurines chemotherapy 308, 309
guanine-7-oxide chemotherapy 307,
308
promyelocytic HL60 cells polyamines
on 96
Hydrocortisone induction of TAT 202
Hydroperoxyeicosatraenoic acid (HPETE)
formation 134, 138, 141
from arachidonic acid 133
on 5-lipoxygenase 135, 136
to leukotriene A_4 133
3α-Hydroxy-5β-androstan-17-one on
preadipocyte differentiation and
G6PD 375
3β-Hydroxy-5β-androstan-17-one on
preadipocyte differentiation and
G6PD 375
17β-Hydroxy-5β-androstan-3-one on
preadipocyte differentiation and
G6PD 375
7-Hydroxyguanine *see* Guanine-7-oxide
7-Hydroxymethotrexate formation 148, 149
3β-Hydroxy-5α-pregnan-20-one on
preadipocyte differentiation and
G6PD 375
Hydroxyurea
on nucleotide reductases 288
-resistant CHO cells 289
-resistant mouse L cells 288

Hypoxanthine-guanine
phosphoribosyltransferase (HGPRT, hypoxanthine phosphoribosyltransferase, HPRT, EC 2.4.2.8)
activation of guanine-7-oxide 304, 315
in liver and hepatoma 3924A
kinetic parameters 341
substrate levels 342
in purine salvage 337
levels in human lymphoblast lines 303
Hypoxanthine protection against guanine-7-oxide 304, 305

IMP dehydrogenase (EC 1.1.1.205)
compared with salvage enzyme 337
in liver cell and hepatoma 3924A
kinetic parameters 341
substrate levels 342
IMPY (pyrazoloimidazole) on ribonucleotide reductases 288
Indomethecin on preadipocyte differentiation 370
Inhibitor 1 243
deinhibitor protein and 260
divalent cations on 253
phosphatase activity of PCS phosphatases and 248, 262
phosphorylation sites 259
regulation of ATP, Mg dependent protein phosphatase 262
Inhibitor 2 *see* Modulator protein
Inositol 1 : 2-cyclic-4-bisphosphate (IcP_2) 118, 129
Inositol cyclic phosphate pathway, functional significance 128
Inositol 1 : 2-cyclic phosphates (IcP)
formation 118, 119
identification 119–122
Inositol cyclic polyphosphates 118
Inositol 1 : 2-cyclic-4,5-trisphosphate (IcP_3) formation 118, 128, 129
Inositol monophosphate, RHC80267 on 128
Inositol-1,4,5-trisphosphate (IP_3)
Ca release by 117
formation 117
Insulin
induction of TAT 201
on glucose balance 66, 68–70
on lactate balance 68, 69
on preadipocyte differentiation 370–373
on SDH induction in rats 46, 47
regulation by nervous system 66
6-Iodoacetamidofluorescin (6-IAF) staining of nucleosomes 279
Ionophore A23187 on TAT activity 45
Ischemia
on concentration of purine
bases 339
nucleosides 339
nucleotides 339
on concentration of pyrimidine
bases 338
nucleosides 338
nucleotides 338
Isoproterenol on blood glucose 49, 51
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine *see* H7

Ketone body metabolism in liver 66–68, 78

Lactate control in liver 66–69, 73, 77, 79–81, 84
Lactobacillus casei
DHFR 11, 12
thymidylate synthase from 158
Leukocytes
diamide on 179
membrane, 5-lipoxygenase and 137–142
MonoQ pass-through fraction (MQ-PTF) 135
5-lipoxygenase stimulation 137–140
membrane association 139, 140, 143
Leukotriene C_4 (LTC_4)
metabolism 211–222
genetic polymorphism 220
in mercapturic acid pathway 212
in primates 219
stimulation of systemic production 218
uptake by rat hepatocytes 214, 221
uptake by rat hepatoma AS-30D 214, 221
Leukotriene D_4 (LTD_4) in mercapturic acid pathway 212
Leukotriene D_4 dipeptidase (EC 3.4.13.11)
assay 213
bestatin on 216
cilastatin inhibition 216
in mercapturic acid pathway 212
inhibition on hepatoma cells 215, 216
penicillamine inhibition 216
Leukotriene E_4 (LTE_4)
in blood plasma 218
in mercapturic acid pathway 212
in monkey bile 219, 222
shock symptoms and 220, 222
uptake by rat hepatocytes 214
uptake by rat hepatoma AS-30D 214
Leukotrienes
biosynthesis 142

physiological function 133
Liposomes interactions with nuclei 273
5-Lipoxygenase (EC 1.13.11.12), multiple regulatory factors and 133–143
activation by HPETEs 135, 136
assay 134
optimization 136, 137
ATP dependence 136, 138
Ca dependence 136–139, 142
MQ-PTF stimulation 137–140
properties 137
purification 135
reactions catalyzed 133
regulation 142
requirements 134, 142
stimulatory factors 138, 141, 142
Lipoxygenases, function and mode of action 133, 142
Liver
diamide on 179, 182
metabolism, regulation by hepatic nerves 63–85
alpha-blocker 66, 68
ammonia 66–68, 78
beta-blocker 66, 68
blood reservoir 83
calcium 81, 82, 84
function 83
glucagon 66, 67, 69, 83
glucose 66–68, 77–81, 83
glutamine 68, 78
glycogen phosphorylase 80
glycogen synthase 1 80
insulin 66, 68–70, 83
ketone body 66–68, 78
lactate 66–69, 73, 78–81, 84
noradrenaline 66–68, 76, 77, 79
parasympathetic nerves 66, 68–70
portal flow 67, 71, 79, 84
pyruvate kinase 80
sodium nitroprusside on 77, 85
sympathectomy 64, 70, 77, 78
sympathetic nerves 66, 67
urea 66, 67, 78
perfusion
calcium free 81, 82
hemodynamics evaluation 65
nerve stimulation and 64, 65
orthograde 77
retrograde 77, 78
via portal vein 64, 73
via portal vein and artery 64, 73, 74
protein mixed disulfides 177, 186
thiol redox state perturbance 178
thiol release
agents on 183
feedback system 185
LTC, LTD, LTE *see* Leukotriene
LTD_4 dipeptidase *see* Leukotriene D_4 dipeptidase
Lung
diamide on 179
thiol redox perturbance 178

6-Mercaptopurine
antitumor activity 308, 309
structure 310
Mercapturic acid pathway 212
Methionine on polyglutamylation 150
Methionine synthase (EC 2.1.1.13)
binding sites for folylpolyglutamates 168
folate metabolism and 160
methyltetrahydropteroylglutamine and 166, 167
preparation and assay 158, 159
Methotrexate
-aquaCisplatin complex 19, 20, 22
glutamylation, methionine on 150
metabolism in hepatocytes and hepatoma cells 147–154
on folate concentration 151, 152
polyglutamates
chain length 149
formation rates 149
hydrolysis 149
polyglutamylation 157
transport inhibition by platinum tetrahydrofolate 26
3β-Methyl-5-androsten-17-one
on DMBA binding 361
on mouse tumor induction 360
Methylenetetrahydrofolate dehydrogenase (EC 1.5.1.5)
folate metabolism and 160
folylpolyglutamate affinity 159, 168
folylpolyglutamate inhibitor affinity 161, 168
Methylenetetrahydrofolate reductase (EC 1.5.1.20)
folate metabolism and 160
folylpolyglutamate affinity 159, 168
folylpolyglutamate inhibitor affinity 161, 162, 168
methotrexate and 158
methyltetrahydropteroylglutamate and 165
Methylene tetrahydropteroylpolyglutamate substrates for thymidylate synthase 163, 164
Methylglyoxal-bis(guanylhydrazone) MGBG on polyamine levels 94
1-Methyl-3-isobutylxanthine on preadipocyte differentiation 370, 371, 373

Methylmercaptopurine riboside
antitumor activity 308, 309
structure 310
S-Methyl-5′-methylthioadenosine ($AdoS^+(CH_3)_2$)
inhibition of SAPT 111
synthesis 108
α-Methylornithine inhibition of ODC 95
5-Methyltetrahydrofolate-aquaCisplatin complex 19, 20
Methyl tetrahydropteroylglutamate
folate pool and 164
methionine from 166, 167
Methyl tetrahydropteroylpolyglutamate, folate transport and 157
5-Methylthioadenosine phosphorylase (MTA phosphorylase, EC 2.4.2.28) in polyamine metabolism 92, 93
Mitogenesis DHEA on 361–364
Modulator protein (Inhibitor 2) 247, 249, 255
deinhibitor protein and 260
regulation of ATP,Mg-dependent protein phosphatase 262
Monkey
kidney cell line BSC-1 226
EGI on 230
growth inhibitor from 234
LTC_4 metabolism in 219
LTE_4 in bile 219, 222
Mouse
aging, DHEA on 368, 369
AKR2B cell line soft agar growth 230
autoimmunity DHEA on 368, 369
diabetes
DHEA protection 367
steroids on 367
Ehrlich ascites tumor cells
polyamine inhibitors on 96
polyamine levels in 98
ribonucleotide reductase 290
subunits during growth 291, 292
embryo fibroblast 3T3 lines 226
EGI on 230
growth inhibitor from 234
embryo fibroblast 3T3-F442A cells
differentiation to adipocytes, agents on 372
embryo fibroblast 3T3-L1 cells
differentiation to adipocytes
inducing agents 370
inhibition by 16α-bromoepiandrosterone 371–374
inhibition by DHEA 361, 371
inhibition by steroids of differing structures 375
inhibition reversal by ribonucleosides 376, 377
sequence of 370
Friend erythroleukemia (MEL) cells
differentiation, polyamine levels on 96
Friend erythroleukemia (MEL) nuclei
phospholipids on macromolecules and ultrastructure 277
PS on histones 276
single gene monitoring in 275
Krebs ascites cells methotrexate on 153
L cells (HU resistant) ribonucleotide reductase 288, 289
leukemia L1210 cells
antipurine chemotherapy 308, 309
culture 302
folates in 20–24
GAR transformylase 329
guanine-7-oxide chemotherapy 307, 308
guanine-7-oxide cytotoxicity and protection 303, 305, 306
guanine-7-oxide on macromolecular synthesis 310–312
guanosine-7-oxide 5′-triphosphate 315
polyamine inhibition in 95, 98
ribonucleotide reductase, cell cycle and 291, 292
leukemia P388 chemotherapy
antipurines 308, 309
guanine-7-oxide 307, 308
Lewis lung carcinoma, guanine-7-oxide cytotoxicity 303
lymphoblast L5178Y *in vivo*
glucocorticoids on 194, 195, 202, 203
lymphoma MC-3-3 cells ribonucleotide reductase in 289
lymphoma S49 ribonuclease reductase M2 subunit 291, 292
mammary carcinoma 16 c
antipurine chemotherapy 308, 309
guanine-7-oxide cytotoxicity 303
melanoma B16 chemotherapy
antipurine 308, 309
guanine-7-oxide 307, 308
melanoma EMT6, DFMO on growth 98
obese
DHEA binding 361
DHEA on weight gain and food intake 364, 365
tumorigenesis, DHEA on 357, 358
organs mitogenesis, DHEA on 362
sarcoma M5076, guanine-7-oxide chemotherapy 307, 308
SV3T3 cells inhibition of polyamine synthesis in 107, 110, 111
TA3 cells ribonucleotide reductase M2 subunit 291, 292

tumorigenesis DHEA on 357–360
weight gain and food intake DHEA on 364, 365
MQ-PTF *see* Leukocyte
Multifunctional polypeptides (GAR synthetase, EC 6.3.4.13; AIR synthetase, EC 6.3.3.1; GAR transformylase, EC 2.1.2.2)
from chicken liver 320, 327
from *D. melanogaster* 327, 329
from *S. cerevisiae* 320
from *S. pombe* 320, 329
interspecies sequence homologies 329, 331
Multisubstrate adduct inhibitors of aminopropyltransferases 107–112
structures 109
Muscle cells, diamide on 179
Myosin light-chain phosphatase 248, 257

NADPH
binding to DHFR 3
folate reduction and 165
orientation in ternary complex 12, 13
substrate protection 7
-trimethoprim cooperativity 8, 11, 12
Neisseria gonorrhoeae DHFR 4
2,4-diamino-5(3-methoxybenzyl)-pyrimidine binding 11
trimethoprim and 8, 11, 13
Neuromuscular junction, diamide on 179
Noradrenaline overflow 66–68, 76–79
Nuclear
matrix phospholipid binding 272, 273
proteins, phospholipids on 276, 277
ultrastructure, phospholipids on 276, 277, 280
Nuclei
lipids on 272
-liposome interactions 273
Nucleic acid metabolism, lipids on 272
Nucleobase concentrations
in rat hepatoma 340
in rat liver 337–340
in rat plasma 340
ischemia on 338–340
Nucleoside concentrations
in rat hepatoma 340, 341
in rat liver 337–341
in rat plasma 340, 341
ischemia on 338–340
Nucleoside 5′-triphosphates allosteric regulation of ribonucleotide reductase 287
Nucleosome
core modifications by PS 277, 279
core units preparation 278
fiber from solenoid fiber 276
unfolding PS and 271–281
Nucleotide
biosynthesis rate limiting and salvage enzymes 336
concentrations, ischemia on 338–340

Obesity, DHEA on 364–368
Ornithine, polyamine biosynthesis and 91, 92
Ornithine decarboxylase (ODC, EC 4.1.1.17)
assay 195
BES on 95
DFMO on 93–100
during development 95
in tumor cells 98
induction
by dexamethasone, GPAs on 197–199
by glucocorticoid 192
in Adx rats 197–200
inhibition by PLP-Orn 109
α-methylornithine on 95
MGBG on 94
polyamine biosynthesis and 91, 92
promoting agents on 97
turnover 92
Oxidoeicosotetranoic acid *see* Leukotriene A_4

PAF on GSH release 183
Pancreatic
islets, diamide on 179
minilobules stimulation
caerulein 123
carbamylcholine 118, 127
Parasympathetic nervous system 66
expression in absence of sympathetic effects 68–71
function 83
PCS_C phosphatases
isolation 244
polycation sensitivity 250, 265
subunits 246
PCS_{H1} phosphatase 243, 264
deinhibitor protein and 258, 260, 261
divalent cations on 254
mol. wt. 244
phosphatase
$2A_1$ and 247
activity 248
IB and 249
polycation sensitivity 250, 265
purification 244
smooth muscle phosphatase and 250

subunits 245, 246
PCS_{H2} phosphatase 243, 264
deinhibitor protein and 258, 260, 261
divalent cations on 254
mol. wt. 244
phosphatase activity 248
polycation sensitivity 250, 265
protamine concentration and 251, 252
purification 244
subunit pattern 245, 246
PCS_L phosphatase 243, 264
divalent cations on 254
mol. wt. 244
phosphatase
II and 249
$2A_2$ and 247
activity 248
polycation sensitivity 250, 265
purification 244
subunit pattern 245, 246
PCS_M phosphatase 243, 264
divalent cations on 254
histone H1 and 249
inhibitor 1 phosphatase and 243, 245, 247
liver protein phosphatase and 250
mol. wt. 244
phosphatase activity 248
polycation sensitivity 250, 265
purification 244
Penicillamine
in rheumatoid arthritis, side effects 217, 218
inhibition of LTD_4 dipeptidase 216, 217, 222
Pentose phosphate pathway, reversible stimulation 180
Peroxidase (EC 1.11.1.7) inhibition of lipoxygenase 141
Pentolamine on rat liver
metabolism 66, 68
SDH and TAT induction 41
L-Phenylephrine
on blood glucose 49, 51
on GSH release 183
Phorbol derivatives on dexamethasone induced TAT 195, 196
Phorbol 12-myristate 13-acetate (PMA)
on amylase release 128
on cGMP formation 127, 130
on inositol monophosphate levels 128
on TAT induction 45, 46
Phosphatase S 249, 257
Phosphatidylcholine (PC)
on nuclear ultrastructure 277
on RNA synthesis 274, 275, 277
Phosphatidylinositol (PI)
cleavage 117
in phosphoinositide signalling system 118
in RNA synthesis 275
loss from brain cortex 125
loss on minilobule stimulation 123, 129
Phosphatidylinositol-4,5-biphosphate (PIP_2)
cleavage 117
Phosphatidylinositol-4-phosphate (PIP)
cleavage 117
in phosphoinositide signalling system 118
Phosphatidylserine (PS)
induced nucleosome unfolding 271–281
multilamellar vesicles (MLV)
preparation 278
on fiber transition 276
on nuclear proteins 277
on nuclear ultrastructure 277
on nuclease accessibility 277
on nucleosome core modifications 277
on protein kinase C 272
on RNA synthesis 274–277
Phosphofructokinase 2 (PFK2, ATP : D-fructose 6-phosphate 2-phosphotransferase, EC 2.7.7.-) in rat liver
adrenalectomy and 40
α-adrenergic system control 43
assay 33
5-azacytidine on 56
control mechanism 32
during development 39, 40
in suckling rats, gonadol steroids on 53
promoter binding sites 54
Phosphoinositide phosphodiesterase in α-adrenergic system 47
Phosphoinositide signalling system reactions of 118
Phosphoinositides 117–130
Phospholipase C (EC 3.1.4.3)
inositol cyclic phosphates and 128
liberation of inositol phosphates 118, 119, 123, 130
on nuclear matrix 272
Phosphomonoesterase in IcP formation (EC 3.1.3.1–2) 118
N-(5'-Phosphoribopyridoxyl) ornithine (PLP-Orn)
structure 109
synthesis 108
5-Phosphoribosyl pyrophosphate amidotransferase (PRPP amidotransferase, amidophosphoribosyltransferase EC 2.4.2.14)
in PRA preparation 323
PRA transfer and 326
Phosphoribosylamine (PRA)
characterization 319–332

anomerization 324, 332
formation 319, 323, 324, 326
NMR studies 323, 325, 332
spectroscopic identification 323–325
stability 319, 325, 326
structure 319
transfer from PRPP amidotransferase to GAR synthetase 326
Phosphorylase *a* PCS phosphatases and 251, 252, 257, 258
Phosphorylase *b* PCS phosphatases and 257
Phosphorylase kinase (EC 2.7.1.38)
on protein phosphatases 249
PCS phosphatases and 247, 263
Platelet-derived growth factor (PDGF) 225, 230
Platinum-folate compounds 17–27
inhibition of folate synthesis 24
table of 20
Platinum tetrahydrofolate
inhibition of DHFR 24, 25
inhibition of methotrexate transport 26
possible analogs 25
structure 19
Pokeweed mitogen mitogenesis, DHEA on 363, 364
Polyamine biosynthesis 107–112
inhibition
AdoDATAD 110
AdoDATO 110
and cell growth 111
DFMO 110
DFMO + AdoDATO 111
drug design 108
pathways 108
Polyamine oxidase in polyamine biosynthesis 92, 93
Polyamines
biosynthesis inhibitors 93–95, 110, 111
carcinogenesis and 97
cell cycle and 96
in cell regulation 241
in growth, development and differentiation 95, 96
in hypertrophy 96
in normal and cancer cells 91–100
metabolism 91–93
protein phosphorylation and 241
transformation and 97
Polyanion treatment of nuclei 276
Polycation stimulated protein phosphatases (PCS protein phosphatases)
classification 242–244
common subunits 245, 246
comparison with other protein phosphatases 247–250
effects of
ATP 253, 254, 261
calcineurin 247, 253
calmidazolium 247
calmodulin 247, 253, 254
divalent cations 253
ethanol 255
heparin 256
histone H1 249–251, 254, 257
inhibitor 1 247, 255, 257
mercaptoethanol 255
modulator 247, 255
NaF 254
phosphate 253, 254, 261
polyamines 263
polycations 247, 250–253, 265
polylysine 250, 254, 257
protamine 250, 257
SDS 255
substrate 251, 252, 258, 265
trifluoperazine 247, 254
Triton 255
trypsin 252, 256
from various sources 242
inhibitor 1 phosphatase activity of 262
latent 249, 256
metabolic role 261
phosphopeptide substrates 258, 259
physical properties 244–247
primary structure requirements 258, 260
regulation 263, 264
specificity 257
Polyglutamate synthesis in hepatocyte and hepatoma cells 147–154
Polylysine on PCS phosphatases 250, 254, 257
PRA *see* Phosphoribosylamine
Prazosin
binding to α-adrenergic receptors 48, 49
displacement by norepinephrine 49, 50
Preadipocytes *see* Mouse embryo fibroblast 3T3, F442A and L1 cell lines
Progesterone
antidiabetic action 367
on SDH, TAT and PFK2 in suckling rats 53
Propanolol on liver metabolism 66, 68
Prostaglandin E in brain cortex 125, 126
Prostaglandin F
in brain cortex 125, 126
on preadipocyte differentiation 370
Protamine stimulation of PCS phosphatases 250, 251, 257
Protein kinase A (cAMP-dependent) regulatory subunit 45
Protein kinase B (Ca-dependent)
activation 118

α-adrenergic system and 45
Protein kinase C (ATP:protein phosphotransferase, EC 2.7.1.37)
activation by DG 117, 127, 130
activators and GPA activity 192, 195, 204
α-adrenergic system and 44, 47
in glucocorticoid action 205
inhibitor H7 203, 204
phospholipid-dependent activity 271, 272
Protein kinases
growth control and 234
roles in liver enzyme induction 44
Protein mixed disulfides with glutathione (protSSG) 146, 185
glucose-6-phosphate dehydrogenase and 180, 181
GSSG and 177
Protein phosphatase (ATP, Mg-dependent protein phosphatase EC 3.1.3.16) 242
aortic muscle phosphatase and 248
deinhibitor protein on 260
forms of 243
heparin on 255
inhibitor phosphorylase and 243
PCS protein phosphatases and 247, 262
specificity 258
Protein phosphatases (*see also* Polycation stimulated protein phosphatase)
regulation and specificity 241–265
Protein
oxidation, stress and 185
SH groups, inflammation and 184
S-thiolation 176–178, 185
synthesis, inhibition by guanine-7-oxide 312, 315
Proteus mirabilis GSA from 191
Pteroylpolyglutamates inhibition of thymidine synthase 163, 164
Purine metabolism in ischemia 339
Purine rate-limiting enzymes of *de novo* biosynthesis 336, 337
in liver and hepatoma 3924A
kinetic parameters 341
substrate concentrations 342
Purine salvage enzymes 336, 337
in liver and hepatoma 3924A
kinetic parameters 341
substrate concentrations 342
Putrescine (Put)
biosynthesis 92, 93
distribution 91
during development 95
during transformation 97
in AdoDATAD treated cells 111
in mouse pancreas 241
Putrescine aminopropyl transferase *see* Spermidine synthase
Pyrazoloimidazole *see* IMPY
Pyridoxal phosphate/$NaBH_4$ on ribonucleotide reductase 289
Pyrimidine metabolism in ischemia 338
Pyrimidine rate-limiting enzymes in *de novo* biosynthesis 336, 337
in liver and hepatoma 3924A
kinetic parameters 342, 343
substrate concentrations 342–344
Pyrimidine salvage enzymes 336, 337
in liver and hepatoma 3924A
kinetic parameters 343
substrate concentrations 343, 344
Pyruvate kinase (EC 2.7.1.40) in liver 80, 85

R59022 *see* Diglyceride kinase inhibitor
Rabbit
serum, growth inhibitor from 229
skeletal muscle protein phosphatases 247–249
Rat
adrenalectomized 32
aging DHEA on 368, 369
AH130 tumor growth inhibitory factor 233
ascites hepatoma line AS-30D
culture 212
cysteinyl leukotriene uptake by 214
LTC_4 metabolites and 215
autoimmunity, DHEA on 368, 369
hepatocytes
cysteinyl leukotriene uptake by 214
FPGS in 150
γ-glutamyl hydrolase in 150, 153
methotrexate glutamylation in 150, 153
methotrexate metabolism in 148–150, 153
TAT induction in 198, 199, 204
hepatoma 3924A cells
culture 336
dipyridamole on 344–347
nucleobase concentrations 340
nucleoside concentrations 340, 341
purine enzymes 341, 342
pyrimidine enzymes 342, 344
hepatoma H-11-EC3 (H35) cells
FGPS in 150, 153
γ-glutamyl hydrolase in 150, 152, 153
glutamylation rates in 151, 153
methotrexate glutamylation in 150, 153
methotrexate metabolism in 148–150, 153
hepatomas of different growth rates, polyamine levels in 98

kidney cell line NRK 226
soft agar growth 230
TGF-β assay and 227
TGF-β on 231
liver α-adrenergic signal receptor-transducer system 47–51
blood-glucose stimulation 50, 51
liver epithelial BRL cells 225
growth 228
growth, EGI on 230, 232, 234
growth inhibitor from 233
growth, rat serum on 229
liver epithelial E-3 cells, aflatoxin and DHEA on 360
liver epithelial (transformed) RSV-BRL cells 225
characteristics 228
growth, EGI on 232, 234
growth inhibitor from 233
growth, rat serum on 229
loss of control sensitivity 235
liver nuclei
phospholipids on macromolecules and ultrastructure 277
transcription in 274
liver
nucleobase concentrations 337–341
nucleoside concentrations 337–340
perfused 79, 85
purine enzymes 341, 342
pyrimidine enzymes 342–344
regenerating, ribonucleotide reductases in 288, 291, 292
plasma
nucleobase concentrations 340
nucleoside concentrations 340, 341
Rhodamine sarcoma growth inhibitory factor 233
tumorigenesis DHEA on 359
weight gain and food intake DHEA on 366
Yoshida sarcoma growth inhibitory factor 233
Reticulocytes, diamide on 179
RHC80267 *see* Diglyceride lipase inhibitor
Ribonucleosides protection of preadipocyte differentiation system 376, 377
Ribonucleotide pools, guanine-7-oxide on 312, 313
Ribocnucleotide reductase (EC 1.17.4.1) *see also* individual nucleotides
activity during cell cycle 287, 291, 292
allosteric regulation 292–294
enzyme complex 295
non-competitive inhibition 290
dNTP regulation of 287, 288
nucleotide channeling and 294–296
properties 287
substrate specificity 287–290
subunits
coordinate regulation 290–292
effector binding (M1) during cell cycle 290–292
non-heme iron (M2), limiting 291, 292
separation 291
unresolved issues 287–296
RNA maturation, phospholipids on 277
RNA polymerase activity phospholipids and 274
RNA synthesis
G6PD inhibition and 361
in isolated nuclei 273, 274
PC on 274, 275, 277
PI on 275
PS on 274–277
Rous sarcoma virus (RSV)
on cell polyamine levels 97
transformed cell lines 226
properties 228

Saccharomyces cerevisiae
DHFR from 4, 5, 13
GAR and AIR synthetases 320, 331
Schizosaccharomyces pombe GAR and AIR synthetases 320, 330
Scott equation, DHFR assay and 4
Sea urchin eggs diamide on 179
Serine dehydratase (SDH, L-serine hydrolase, EC 4.2.1.13)
adrenalectomy on 34–40, 51–54
assay 33
5-azacytidine on 56, 57
DOC on 36–38
during rat development 36–38, 51
placenta on 47
epinephrine on 43, 44
glucagon on 44
in Adx,Gnx rats 52
in suckling rats
adrenalectomy on 51
aminophylline on 42
epinephrine on 43
gonadal steroids on 53
glucagon on 41, 46
insulin on 46
phentolamine on 41, 43
inducibility, developmental changes 56
induction 31, 40
α-adrenergic system, glucagon model 44
precocious 34
promoter binding sites 54
L-Serine hydrolase *see* Serine dehydratase

Serine hydroxymethyltransferase (EC 2.1.2.1)
folate metabolism and 160
folylpolyglutamate affinity 159, 168
folylpolyglutamate inhibitor affinity 161, 168
Serum
growth factors in 229
on preadipocyte differentiation 370–373
Solenoid fiber and PS treatment of nuclei 276, 280
Spd/Spm-*N*'-acetyltransferase (SAT) in polyamine biosynthesis 92, 93
Spermidine (Spd)
biosynthesis 92, 93
distribution 91
during transformation 97
in cell-free systems 241
in differentiation 96
PCS phosphatase stimulation 251, 263
N^1,N^8-bis(ethyl) Spermidine (BES) growth inhibition 95
Spermidine aminopropyltransferase *see* Spermine synthase
Spermidine synthase (Putrescine aminopropyltransferase, PAPT, EC 2.5.1.16)
AdoDATAD on 110
AdoDATO on 110
inhibitors of 107
polyamine biosynthesis and 92
Spermine
biosynthesis 92, 93
inhibition 94
distribution 91
in cell-free systems 241
PCS phosphatase stimulation 251, 263
pool, AdoDATO on 110, 111
Spermine synthase (Spermidine aminopropyltransferase, SAPT, eC 2.5.1.22)
AdoDATAD on 110
AdoDATO on 110
inhibitors of 107
polyamine biosynthesis and 92
Stearic acid release from minilobules 123
RHC80267 and 124
Steroid
hormones on liver enzyme induction 51–54
structure
G6PD inhibition and 374–376
inhibition of differentiation and 374–376
S-thiolation hypothesis 175
Streptomyces species (ATCC39364) guanine-7-oxide producing 301, 315
Superoxide generation DHEA on 360
Sympathetic nervous system 66
arterial plexus 64, 74, 75
calcium requirement 81
extrahepatocellular mechanism 76–78
function 83
hepatic stimulation, hemodynamic effects 71, 74, 75
hepatic stimulation, metabolic effects of 66–68
portal plexus 65, 74, 75
species comparison 79, 85
suppression with α- and β-blockers 68

Testosterone
on preadipocyte differentiation and G6PD 357
on SDH, TAT and PFK2 in suckling rats 53
12-O-Tetradecanoylphorbol-13-acetate (TPA)
GPA activity 192, 194
hormonal specificity 201
mitogenesis, steroids on 361, 363, 364
on dexamethasone-induced ODC 197, 198
on dexamethasone-induced TAT 195, 196, 198–200
on endogenous glucocorticoids 197
on L5178Y tumor growth 202
on steroid-induced TAT 202
stimulated tumorigenesis, steroids on 335, 360
Tetrahydrofolate-diaquacisplatin complex 19, 20
5,6,7,8-Tetrahydrofolate : $NADP^+$ oxidoreductase *see* Dihydrofolate reductase
6-Thioguanine
antitumor activity 308, 309
on human lymphoblast cell lines 304
structure 310
Thiol
oxidation, transport processes and 180
redox state
perturbance and cellular response 178–181, 184
protein S-thiolation and 185
release from protein 176
Thymidine incorporation DHEA on 361–364
Thymidine kinase (EC 2.7.1.21)
in liver and hepatoma 3924A 341
kinetic parameters 342, 343
substrate levels 343, 344
in pyrimidine salvage 337

Thymidylate synthase (EC 2.1.1.45)
bacterial 158
folate metabolism and 160
folylpolyglutamate affinity 159, 168
folylpolyglutamate inhibitor affinity 161, 168
inhibition by pteroylpolyglutamates 163, 164
inhibition by dTMP 164
isolation and assay 158
methotrexate and 158
methylene tetrahydropteroylpolyglutamate substrates 163, 164
dTMP inhibition of thymidylate synthase 164
Triacylglycerol
preadipocyte differentiation and 370
weight gain in mice and 364
Transcription and phospholipid interaction 275, 277, 280
Transformation
DHEA on 363, 364
polyamine metabolism and 97
Transforming growth factor (TGF-β)
assay 227
from human platelet extract 230, 231
N-terminal sequence 232
soft agar growth stimulation 230
Triamcinolone-acetonide
induction of TAT 202
on L5178Y tumor growth 202, 203
Triciribine phosphate
antitumor activity 308, 309
structure 310
Trimethoprim (TMP) 4
analogs 8–11
inhibition of DHFR 8
location in DHFR complexes 12, 13
-NADPH cooperativity 12
Trypsin on PCS phosphatases 252, 256
Tryptophan dioxygenase induction 31, 54
Tupaia liver, perfused 79, 85
Tyrosine aminotransferase (TAT, L-tyrosine-2-oxyglutarate aminotransferase, EC 2.6.1.5) in rat
adrenalectomy on 36, 41, 196–201
assay 33, 195
DOC on 36
in fetal rat liver slices 45
in suckling rats
glucagon on 41
gonadal steroids on 53
phentolamine on 41
induction 31, 40
amplification time course 197, 198
by dexamethasone, GPAs on 195–200
by glucagon, GPAs on 201
by glucocorticoid 191, 192
by insulin, GPAs on 201
by various steroids, TPA on 202
in rat hepatocytes 198, 199, 204
in vivo 194, 196, 197
inhibition by H7 204
placenta on 47
precocious 34
promoter binding sites 54
Tyrosine kinases and growth factors 225
L-Tyrosine : 2-oxoglutarate aminotransferase
see Tyrosine aminotransferase

UDP reductase
allosteric effectors 293, 294
from Ehrlich tumor cells 288
inhibition 290
Urea production, control in liver 66, 67
Urethan carcinogenesis in mouse, DHEA on 358
Uridine kinase (EC 2.7.1.48)
in liver and hepatoma 3924A
kinetic parameters 342, 343
substrate levels 343, 344
in pyrimidine salvage 337

Vasopressin on GSH release 183

Xanthine oxidase (EC 1.2.3.2) in rat hepatoma 3924A 340

Yeasts DHFR from 4